WO2012163771A1

WO2012163771A1 - Magea3 binding antibodies

Info

Publication number: WO2012163771A1
Application number: PCT/EP2012/059644
Authority: WO
Inventors: Christoph Esslinger; Michael HÖCKER; Martin Treder; Alexander Knuth; Elke JÄGER
Original assignee: Ct Atlantic Ltd.; Universität Zürich
Priority date: 2011-06-03
Filing date: 2012-05-23
Publication date: 2012-12-06
Also published as: JP2014518889A; EP2714742A1; US20140093514A1

Abstract

The present disclosure relates to MAGE A3 binding antibodies.

Description

MAGE A3 binding antibodies

FIELD OF THE INVENTION

The present invention relates to MAGEA3 binding antibodies or binding fragments thereof. The present invention further relates to the use of such MAGEA3 binding antibodies or binding fragments thereof, in particular hyper-pro! iterative diseases and methods for treating diseases, in particular hyper-proliferative diseases with such combinations.

BACKGROUND OF THE INVENTION

In cancer therapy, it is a general aim to treat the afflicted tissues as efficiently and selectively as possible. Therapeutic monoclonal antibodies have been conceived as a class of pharmaceutical ly active agents, which should allow tumor selective treatment, by targeting tumor selective antigens or epitopes.

However, in some cancers, for example those associated with human growth factor receptors such as HER-2 R or EGFR, epitopes targeted by therapeutic antibodies are also found on normal tissues explaining adverse side effects upon antibody administration or peripheral sink effects in the pharmacokinetic behavior of such antibodies.

The analogous situation holds true by applying systemically active immune- stimulatory drugs or antibodies applied to stimulate a natural immune response to fight cancer. Such immune-stimulants are for example activators of the innate immune system such as activators of TLR-7 or TLR-9 receptors.

Monoclonal antibodies have nevertheless enjoyed increasing acceptance as therapeutic tools for treating cancer over the past decades. The advent of chimeric antibodies and humanized antibodies significantly contributed to the success of monoclonal therapeutic antibodies as these second and third generation monoclonal antibodies showed improved side-effect profiles compared to the original mice- derived monoclonal antibodies in view of their reduced immunogenicity.

Despite the proven therapeutic efficacy of humanized antibodies, there is an interest in fully human antibodies. However, production thereof is still prone to technical difficulties. For example, generating fully human antibodies in mice in which the antibody encoding genomic regions have been replaced by the human counterpart remains burdensome. Alternative approaches such as phage display lack the natural variability and complexity of the human immune system.

There is thus continuing need for therapeutic monoclonal antibodies which allow for a (tumor) localized mode of act ion and which have an increased chance of meeting regulatory approval. Moreover, there is a wish for cancer therapies in general which allow for improved efficacy. OBJECTIVES AND SUMMARY OF TH E INVENTION it is an objective of the present invention to provide pharmaceutically active agents, which can be used as therapeutic and/or diagnostic tool for treati ng ^'d i agnos i ng human diseases including hyper-proliferative diseases such as cancer. In particular, it is an objective of the present invention to prov ide combinations of pharmaceutically active agents, which can be used to selectively treat hyper-proliferative diseases by ensuring a localized immune reaction in the afflicted tissue. Further, it is an objective of the present invention to provide methods of treating and/or diagnosing patients suffering or suspected of suffering from e.g. from hyper- proliferative diseases such as cancer by making use of such pharmaceutically active agents and such combinations of pharmaceutically active agents. These and other objectives as they w ill become apparent from the ensuing

description hereinafter are solved by the subject matter of the independent claims. Some of the preferred embodiments of the present invention form the subject matter of the dependent claims. Yet other embodiments of the present invention may be taken from the ensuing description.

In a first aspect, the invention relates generally to isolated monoclonal MAGEA3 binding antibodies or binding fragments thereof.

In one embodiment of the first aspect, the invention thus relates to pharmaceutical compositions comprising such isolated monoclonal MAGEA3 binding antibodies or binding fragments thereof.

In another embodiment of the first aspect, the invention thus relates to diagnostic compositions comprising such isolated monoclonal MAGEA3 binding antibodies or binding fragments thereof. Such MAGE A3 binding antibodies or binding fragments thereof may be monoclonal chimeric, humanized or human antibodies or binding fragments thereof. Patient- derived, human, monoclonal antibodies may be preferred.

In another embodiment such MAGE A3 binding antibodies or binding fragments thereof preferentially bind to MAGEA3 over other MAGE isoforms such as MAGE- MAGEA1 , MAGEA4, MAGEA10 and/or optionally even MAGEA2. Preferred exemplary MAGEA3 binding antibodies or fragments thereof may comprise a variable heavy chain and/or a variable light chain of the exemplary antibodies 2 1 B4, 3 1 H 10, 54 B4. 43 B I O, 94G 1 1 , 9A5, 26C9, 20C 1 0. 2G4 or 4D6 or a variable heavy chain and. or a v ariable light chain having at least 80% sequence identity with the variable heavy chain and/or variable l ight chain of the exemplary antibodies 2 1 B4, 3 1 H 1 0, 54B4. 43 B 1 0, 94G 1 1. 9A5, 26C9, 20C 10, 2G4 or 4D6.

Other preferred exemplary MAGEA3 binding antibodies or fragments thereof may- comprise at least one. two or all three of the complementary determining regions

(CDRs) of the exemplary antibodies 21B4, 31H10, 54B4, 43B10, 94G1 1 , 9A5, 26C9, 20C 10, 2G4 or 4D6 w ithin their variable heavy chain and. or variable light chain. Such antibodies may also comprise CDRs within their variable heavy chain and/or variable light chain having at least 80% sequence identity with the CDRs of the exemplary antibodies 21B4, 3 1 1 1 10, 54B4, 43B 10, 94G1 1 , 9A5, 26C9, 20C10, 2G4 or 4D6.

The present invention further relates to pharmaceutical compositions comprising such specific MAGEA3 binding antibodies or binding fragments thereof for use in treating hyper-prol i ferat i ve disease, in particular tumors, which express MAGEA3. The present invention further relates to the use of such specific MAGE A3 binding antibodies or binding fragments thereof in the manufacture of a medicament for treating hyper-prol i ferat i ve disease, in particular tumors, which express MAGEA3. The present invention further relates to methods of treating hyper-proiiferative disease, i particular tumors, which express MAGEA3 by administering to patients such specific MAGEA3 binding antibodies or binding fragments thereof.

Such hyperproliferative diseases preferably include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer.

In one embodiment of this first aspect of the present invention, the pharmaceutical compositions comprising the MAGEA3 binding antibodies or binding fragments thereof do not comprise a compound capable of activating the immune system. In another embodiment of this first aspect of the present invention, the

pharmaceutical compositions comprise the MAGEA3 binding antibodies or binding fragments as the sole pharmaceutically active agent.

In other embodiments of the first aspect of the invention, the MAGEA3 binding antibodies or binding fragments thereof as described herein are used as a diagnostic tool, e.g. for diagnosing patients suffering from hyperproliferative diseases as mentioned herein. It can be preferred to use such antibodies to diagnose the occurrence and. or development of e.g. hyperproliferative diseases, which express MAGEA3 and. or MAGEA6. Such hyperproliferative diseases may include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer.

In one embodiment, the present invention thus relates to a diagnostic composition comprising the MAGE A3 binding antibodies or binding fragments described herein. Such diagnostic compositions may be for use in diagnosing occurrence and/or development of e.g. hyperproliferative diseases, which express MAGE A3 and/or MAGEA6. Such hyperproliferative diseases may include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer.

In another embodiment, the invention relates to MAGEA3 binding antibodies or binding fragments thereof as described herein for use in diagnosing

hyperproliferative diseases. These diseases may express MAGEA3 and/or

MAGEA6. Such hyperproliferative diseases may include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer.

In another embodiment, the present invention relates to the use of MAGEA3 binding antibodies or binding fragments thereof as described herein in the manufacture of a composition and. or medicament for diagnosing hy pe rprol i fera t i ve diseases. These diseases may express MAGE A3 and/or MAGEA6. Such hyperproliferative diseases may include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and or pancreatic cancer. In yet another embodiment, the present invention relates to a method of diagnosing a hyperprol iferative disease in a human or animal being by using MAGE A3 binding antibodies or binding fragments thereof as described herein These diseases may express MAGEA3 and. or MAGEA6. Such hyperproliferative diseases may include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer.

In a second aspect, the invention relates to a combination of at least one tumor associated antigen (TAA) binding ant ibody or binding fragment thereof and at least one compound capable of activating the immune system. In one embodiment of the second aspect, the present invention relates to a

pharmaceutical composition comprising at least one tumor-associated antigen (TAA ) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system.

As will become apparent from the ensuing description, such TAA binding antibodies or binding fragments thereof preferably bind to CT antigens with NY-ESO- 1 or MAGEA3 being examples thereof. Such antibodies or binding fragments thereof may be monoclonal chimeric, humanized or human antibodies or binding fragments thereof. Patient-derived, human, monoclonal antibodies may be preferred.

Preferred exemplary MAGEA3 binding antibodies or fragments thereof may be the MAGEA3 binding antibodies or binding fragments thereof as mentioned hereinafter. Exemplary NY-ESO- 1 binding antibodies or binding fragments thereof may be those mentioned in EP 1 1 150 527.7.

As will become apparent from the ensuing description, compounds capable of activating the immune response may preferably be selected from at least one natural stimulant or at least co-stimulant of the immune system, agonistic activator of natural stimulants or at least co-stimulants of the immune system, or at least one antagonistic effector of natural inhibitors or at least co-inhibitors of the immune system as described hereinafter. Some preferred exemplary representatives are CD40L, anti- CD40 agonistic antibodies such as CP-870,893 and SGN-40 and anti-CTLA4 antagonistic antibodies such as Tremc! imumab and Ipilimumab.

Preferred exemplary embodiments thus relate to pharmaceutical compositions comprising (i) the MAGEA3 binding antibodies or fragments thereof as mentioned hereinafter, and (ii) CD40L, or anti-CD40 agonistic antibodies such as CP-870,893 and SGN-40, or anti-CTLA4 antagonistic antibodies such as Tremelimumab and Ipilimumab In a preferred embodiment, the pharmaceutical composition may comprise (i) a TAA binding antibody or binding fragment such as the MAGE A3 binding antibodies or binding fragments thereof as mentioned hereinafter, (ii) at least one natural stimulant or at least co-stimulant of the immune system, or at least one agonistic activator of natural stimulants or at least co-stimulants of the immune system and (iii) at least one antagonistic effector of natural inhibitors or at least co-inhibitors of the immune system as described hereinafter. Some preferred exemplary embodiments relate to pharmaceutical compositions comprising (i) the afore-mentioned MAGEA3 binding antibodies or fragments thereof, (ii) CD40L or anti-CD40 agonistic antibodies such as CP-870,893 or SGN-40 and (iii) anti-CTLA4 antagonistic antibodies such as Tremeiimumab and Ipilimumab.

In another embodiment of the second aspect of the invention, the aforementioned pharmaceutically active agents, i.e. the TAA binding antibodies or fragments thereof such as the MAGEA3 binding antibodies or binding fragments thereof as mentioned hereinafter and the compounds capable of stimulating the immune system are not combined within a single pharmaceutical composition but actually are presented in form of a kit consisting of various pharmaceutical compositions wherein the active agents are split at least to some extent between the various pharmaceutical compositions.

For example, one pharmaceutical composition of such a kit may comprise a TAA binding antibody or binding fragment thereof such as a such as the MAGEA3 binding antibodies or binding fragments thereof as mentioned hereinafter while a second pharmaceutical composition may comprise or at least one agonistic activator of natural stimulants or at least co- stimulants of the immune system such as anti- CD40 agonistic antibodies or at least one antagonistic effector of natural inhibitors or at least co-inhibitors of the immune system such as anti-CTLA4 antagonistic antibodies. In embodiments where the kit comprises a TAA binding antibody or binding fragment thereof such as the MAGEA3 binding antibodies or binding fragments thereof as mentioned hereinafter and both at least one agonistic activator of natural stimulants or at least co-stimulants of the immune system such as anti-CD40 agonistic antibodies, and at least one antagonistic effector of natural inhibitors or at least co-inhibitors of the immune system such as anti-CTLA4 antagonistic antibodies, one pharmaceutical composition of such a kit may comprise a TAA binding antibody or binding fragment thereof such as the MAGEA3 binding antibodies or binding fragments thereof as mentioned hereinafter, while a second pharmaceutical composition may comprise at least one agonistic activator of natural stimulants or at least co-stimulants of the immune system such as anti-CD40 agonistic antibodies and a third pharmaceutical composition may comprise at least one antagonistic effector of natural inhibitors or at least co-inhibitors of the immune system such as anti-CTLA4 antagonistic antibodies. In alternative thereof, the second pharmaceutical composition may comprise both at least one agonistic activator of natural stimulants or at least co-stimulants of the immune system such as anti-CD40 agonistic antibodies and at least one antagonistic effector of natural inhibitors or at least co-inhibitors of the immune system such as anti-CTLA4 antagonistic antibodies.

Such kits allow treatment of patients by subsequent and/or at least partially simultaneous administration of the various pharmaceutical preparations, which form the kit and may thus enable a timely optimized treatment regimen of the above- mentioned combinations.

The present invention also relates to a combination of at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof such as the MAGEA3 binding antibodies or binding fragments thereof as mentioned hereinafter and at least one compound capable of activating the immune system for use in treating a disease such as a hyper-pro! iferative disease. The TAA binding antibody or binding

fragments thereof such as the MAGEA3 binding antibodies or binding fragments thereof as mentioned hereinafter and the at least one compound capable of activating the immune system may be selected as described hereinafter.

As is described hereinafter, the combinations of active agents in accordance with the invention, i.e. TAA binding antibodies or fragments thereof such as the MAGE A3 binding antibodies or binding fragments thereof as mentioned hereinafter and compounds which are capable of stimulating the immune system, may provide improved efficacy if patients are subjected to cytotoxic treatment prior to,

simultaneous with or subsequent to administration of the aforementioned pharmaceutical compositions, kits or combinations comprising such active agents. It may be preferred that patients receive such cytotoxic treatment prior to or simultaneous with administration of the aforementioned pharmaceutical

compositions, kits or combinations comprising such active agents.

I f such cytotoxic treatment comprises administration of cytotoxic agents, such cytotoxic agents may be included in the pharmaceutical compositions or kits in accordance with the invention. One exemplary preferred representative of such cytotoxic agents is 5-fluoro uracil (5-FU).

In another embodiment of the second aspect of the invention, the pharmaceutical compositions and kits in accordance with the invention may be used to treat patients suffering or being suspected to be prone to hyper-proliferative diseases, such as cancer.

Preferably, the pharmaceutical compositions and kits in accordance with the invention may be used to treat patients suffering or being suspected to be prone to cancers, which are characterized by the expression of TAAs such as cancers being characterized by the expression of CT-antigens such as MAGEA3. If the TAA binding antibody or binding fragment thereof which is comprised within the pharmaceutical compositions and kits in accordance with the invention is a

MAGE A3 binding antibodies or binding fragments thereof as mentioned hereinafter, the treatment of cancers such as melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and. or pancreatic cancer.

Another embodiment of the second aspect of the present invention thus also relates to a medicament for use in treating a patient wherein a pharmaceutical composition or a kit as described hereinafter is used. TAA binding antibodies or binding fragments may preferably be MAGEA3 binding antibodies or binding fragments thereof and compounds capable of activating the immune response may preferably be selected from at least one natural stimulant or at least co- stimulant of the immune system, agonistic activator of natural stimulants or at least co-stimulants of the immune system or at least one antagonistic effector of natural inhibitors or at least co- inhibitors of the immune system as described hereinafter. In some embodiments, a combination of the MAGE A3 binding antibodies or binding fragments thereof as mentioned herein, anti-CD40 agonistic antibodies such as CP-870,893 and SGN-40 and/or anti-CTLA4 antagonistic antibodies such as Tremelimumab and Ipil imumab are envisaged.

Such medicaments may be used for patients who are subjected to cytotoxic treatment prior to, simultaneous with or subsequent to administration of such medicaments. In one embodiment the cytotoxic treatment may include chemotherapy .

Such medicaments may in particular be used for treatment of hyper-proliferative disease such as cancer.

The present invention in an embodiment of the second aspect of the invention also relates to the use of a pharmaceutical composition or a kit as described hereinafter in the manufacture of a medicament for treating a patient. TAA binding antibodies or binding fragments may preferably be MAGEA3 binding antibodies or binding fragments thereof and compounds capable of activating the immune response may preferably be selected from at least one natural stimulant or at least co-stimulant of the immune system, agonistic activator of natural stimulants or at least co-stimulants of the immune system or at least one antagonistic effector of natural inhibitors or at least co-inhibitors of the immune system as described hereinafter. In some

embodiments, a combination of theMAGEA3 binding antibodies or binding fragments thereof as mentioned herein, anti-CD40 agonistic antibodies such as CP- 870,893 and SGN-40 and/or anti-CTLA4 antagonistic antibodies such as

Tremeiimumab and Ipil imumab are envisaged.

Such medicaments may be used for patients, which are subjected to cytotoxic treatment prior to, simultaneous with or subsequent to administration of such medicaments, in one embodiment the cytotoxic treatment may include

chemotherapy.

The present invention also relates to a method of treating a patient by administering a pharmaceutical composition or a kit as described hereinafter to the patient. TAA binding antibodies or binding fragments may preferably be MAGEA3 bi ding antibodies or binding fragments thereof and compounds capable of activating the immune response may preferably be selected from at least one natural stimulant or at least co-stimulant of the immune system, agonistic activator of natural stimulants or at least co-stimulants of the immune system or at least one antagonistic effector of natural inhibitors or at least co-inhibitors of the immune system as described hereinafter. In some embodiments, a combination of the MAGEA3 binding antibodies or binding fragments thereof as mentioned herein, anti-CD40 agonistic antibodies such as CP-870,893 and SGN-40 and/or anti-CTLA4 antagonistic antibodies such as Tremeiim.um.ab and Ipiiimumab are envisaged.

Such methods may be considered for patients, who are subjected to cytotoxic treatment prior to, simultaneous with, or subsequent to administration of such medicaments. In one embodiment the cytotoxic treatment may include

chemotherapy.

Such methods may be considered for treatment of hyper-proliferative disease such cancer.

FIGURE LEGENDS

Figure 1 Binding of recombinant human monoclonal antibodies to epitopes on

MAGE A3.

Antibodies 21B4, 54B4, 94G 1 1 . 9A5. 3 1 H 1 0, 43 B I O, 2G4, 20E10, 26C9 and 4D6 were analyzed by EL IS A using plates coated with overlapping peptides spanning the entire MAGE A3 -protein. Antibodies 2 1 134, 54B4, 94G1 1 , 9A5, 31H10 and 43B 10 bound to one or several, of the MAGEA3 overlapping peptides (A-F). Antibodies 2G4, 20E 10, 26C9 and 4D6 did not show binding to any of the 20mer MAGE A3 peptides.

Figure 2 Immunoprecipitation of MA.GEA.3 by recombinant human monoclonal

antibodies. Antibodies 21B4, 54B4, 94G1 1 , 9A5, 3 1 H 10, 43 B I O, 2G4, 20C 10 and 26C9 were incubated with ly sates of S -MEE-37 cells endogenously expressing MAGE A3 ( lane B). Antibody precipitated MAGEA3 protein was detected by Western blot using a MAGEA3 speci fic antibody. As controls, antibody alone (lane A) or antibody incubated with, iysate of HEK. 293T ceils not expressing MAGEA.3 (lane C) was used. Figure 3 MAGEA-Family-reactivity of recombinant human monoclonal

antibodies.

A) Recogn ition of MAGEA, but not of MAGEA4 by recombinant human monoclonal ant ibodies. Human antibodies 21B4, 54B4, 94G1 1 , 9A5,

3 1 1 1 1 0,43 B I O, 2G4 and 20C 10 were used to detect recombinant

MAG E A3- ( lane A ) and recombinant MAGEA4-protein ( lane B) in Western Blot analysis. B) MAGEA-Family-ELISA. Serial di l utions of human-derived recombinant antibodies 21B4, 94G1 1 , 9A5 and 2G4 were tested in ELISA for binding to MAGEA l , MAGE A3, MAGEA4 and

MAGEA 1 0. C) Binding of human-derived recombinant antibodies 21B4, 31H10, 94G1 1 and 54B4 to MAGEA3 and MAGEA6.

Figure 4 EC50 determinat ion of recombinant human monoclonal antibodies to

MAGEA3. MAGEA3-ELISA was carried out usingrecombinant

MAGEA3 coated to plastic and serial dilutions of the human monoclonal antibodies 21B4, 54B4, 94G1 1 , 9A5, 31H10, 43 B I O, 2G4, 20C10, 26C9 and 4D6 (A- J). EC50 values are indicated in each figure. Figure 5 Immunohistochemistry analysis of recombinant human monoclonal antibody 21B4 on a selection of human normal and tumor tissues.

A) Normal testis: Selected spermatogonia are stained by 21B4 (arrowheads). No staini g by 2 1 B4 is observed on prostate (B), Lymph node (C), heart tissue (D), and Colon (E). F) Squamous cell carcinoma of the lung: 21B4 specifically stains cancerous infiltrates (circles).

Figure 6 21B4 vs M3H67 in MAG EA-Family-EL ISA . Serial dil ut ions of human- derived recombinant antibody 2 1 B4 and murine mAb M3H67 were tested in ELISA for binding to MAGEA l , MAGEA3, MAGEA4 and MAGEAl 0. Antibodies were used in concentrations of 000ng ml 1250ng/ml, 312.5ng/ml and 78ng/ml. 21B4 binds specifically to

MAGEA.3, M3H67 shows preferential binding to MAGEA4, MAGE1 and MAGEA 10. (Y-axis of graph in logarithmical scale.) Figure 7 2 1 B4 vs M3H67 in Western Blot Analysis. Protein and MAGEA3

containing cell iysate of SK-MEL-37 cells was separated using Gradient SDS PAGE. Proteins were detected after blotting on nitro cellulose membrane using either 21B4 or mAb M3H67 (^g/ml each antibody). Bound antibody was detected using HRP-labelcd goat anti human IgG (2 1 B4) or goat anti mouse IgG (M3H67) secondary antibodies. Arrows mark position of MAGEA3.

Figure 8 Schematic design of such a human-mouse reverse chimera 2 1 B4rc. Figure 9 IHC stainings of normal (non-cancerous) tissue using either 2 I B4rc or

M3H67. 2 1 B4rc shows a staining of distinct spermatogonia (arrow shows representative spermatogonia) of the testis whereas M3H67 stains all spermatogonia and the surrounding interstitial tissue. With Kidney and Pancreas no staining with either antibody is observed.

Fig. 1 0 I HC stainings of cancerous tissue derived from head and neck cancers of three individual patients using either 2 1 B4rc or M3H67. Case 1 shows an overall similar staining by 2 1 B4rc and M3H67. In Case 2, 2 1 B4rc stains cancerous infiltrates which are not recognized by M3H67 and in case 3 a cancerous infiltrate recognized by M3H67 is not stained by 2 1 B4rc.

DETAILED DESCRIPTION OF THE INVENTION

Before the invention is described in detail with respect to some of its preferred embodiments, the following general definitions are provided. The present invention as illustratively described in the following may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein.

The present invention will be described with respect to particular embodiments and with reference to certain figures but the invention is not limited thereto but only by the claims. Where the term "comprising" is used in the present description and claims, it does not exclude other elements. For the purposes of the present invention, the term "consisting of is considered to be a preferred embodiment of the term "comprising of. If hereinafter a group is defined to comprise at least a certain number of embodiments, this is also to be understood to disclose a group, which preferably consists only of these embodiments.

For the purposes of the present invention, the term "obtained" is considered to be a preferred embodiment of the term "obtainable^". I f hereinafter e.g. an antibody is defined to be obtainable from, a specific source, this is also to be understood to disclose an antibody, which is obtained from this source.

Where an indefinite or definite article is used when referring to a singular noun, e.g. "a", "an" or "the", this includes a plural of that noun unless something else is specifically stated. The terms "about^" or "approximately" in the context of the present invention denote an interval of accuracy that the person skilled in the art will understand to still ensure the technical effect of the feature in question. The term typically indicates deviation from the indicated numerical value of ±10%, and preferably of ±5%. Technical terms are used by their common sense. If a specific meaning is conveyed to certain terms, definitions of terms will be given in the following in the context of which the terms are used. The term "Tumor Associated Antigen (TAA)" in its broadest sense relates to factors, which are primarily, if not exclusively expressed in tumors and thus can act as potential immune-therapeutic targets for antibody-based therapy. The primary and preferably exclusive expression of TAAs in tumor tissue ensures that the therapeutic antibody mediated immune reaction will be localized to the tumor only so that the above-described adverse events and effects on pharmacokinetic behavior are observed at least not to the same extent as for therapeutic antibodies which target antigens that are expressed both in tumor and normal tissues.

It is to be understood that expression of such TAAs must be seen before the background of accessibility of such expressed TAAs to antibodies and/or

accessibility of such expressed TAAs to the immune system.

Thus, expression of TAAs may occur on the DNA or RNA level in normal tissue, which, however, does not translate into expression on the protein level. As a consequence such a TAA will not be expressed in normal tissues in an extent that would make it principally available for therapeutic antibodies as such antibodies are commonly understood to recognized antigens and/or epitopes involving stretches of amino acids. Further, there may be tissues such as testis which are not functionally accessible to the immune system, e.g. in the sense that they do not show MHC expression and therefore cannot be targeted by T -cells, and wliich therefore are commonly

considered to be immune privileged. Even if a TAA is expressed in such immune privileged normal tissue, an antibody binding to such a TAA would thus not trigger an immune response in such normal tissue. Again the immune response would be limited to the tumor tissue expressing the TAA.

A preferred group of TAAs are the so-called "cancer/testis antigens (CT-antigens)". This group has emerged as a unique class of TAAs, which are expressed either in diverse tumors or normally in testis, i.e. an immune privileged tissue. An overview on the properties of CT-antigens including information on their genomic coding, function, tumor expression etc. can be found inter alia in Caballero et al, 2009, Cancer Science, 100(1 1), 2014-2021 , the disclosure of which is incorporated by reference particularly with respect to the nature of CT antigens as well as the occurrence and distribution of specific CT antigens within different types of tumors (see e.g. Table 1 of Caballero et al, vide supra).

Detailed information about CT-antigens can be found in http ://www. eta. lncc.br/) . The information provided by this database, in particular with respect to gene families of CT-Antigens. specific family members, their chromosomal local ization, CT identifiers and protein expression patterns in tumors are incorporated by reference.

Examples of CT- Antigens can be found in Table 1.

Table 1 - List of preferred CT-antigens

CT-

Gene family CT-Antigen

Identifier

MAGEA MAGEA 1 CTl .l

AGE A MAGEA2 CT1.2

MAGEA MAGEA3 CT1.3

MAGEA MAGEA4 CT1.4

MAGEA MAGEA5 CT1.5

MAGEA MAGEA6 CT1.6

MAGEA MAGEA 10 CTl .iO

BAGE BAGE CT2.1

GAGE GAGE ! CT4.1

SSX SSX1 CT5.1 ssx SSX2 CT5.2a

SSX SSX4 CT5.4 NY-ESO- I (TA I B CT6.1

NY-ESO-1 CTAGIA

NY-ESO-1 CTAG2 CT6.2a

NY-ESO-1 LAGE-lb CT6.2b

MAGEC1 MAGEC1 CT7.1

MAGEC1 MAGEC3 CT7.2

MAGEC2 MAGEC2 CT10

XAGE XAGE1 CT12. ia

XAGE XAGE2 CT12.2

CT47 CT47A1 CT47.1

FRAME FRAME CT130

The term "CT- Antigen" is used interchangeably both for the gene family as well as for individual members of a gene family. It is to be understood that if in the following reference is made to MAGEA3 binding antibodies or binding fragments thereof, this means that such antibodies bind to the ( T-antigen MAGEA3. Such reference shall always include MAG EA3 binding antibodies or fragments thereof as mentioned hereinafter and in particular the specific antibodies and their sequence homologues as they are mentioned herein such as 21B4, 31H10, 54B4, 43B10, 94G1 1 , 9A5, 26C9, 20C 10, 2G4 or 4D6. The term. MAGEA3 preferably refers to the human MAGEA3 protein and may thus designate a protein comprising an amino acid sequence of SEQ ID No.: 101

If it is stated that an antibody or fragment thereof binds to MAGE A3, this means that the antibody or binding fragments thereof preferably binds specifically to said antigen, i.e. binds the antigen with greater affinity than other antigens. This

particularly means that no other CP-antigens from different gene families such as NY-ESO are recognized by said antibody or binding fragment thereof. For example, an antibody or fragment is specific for its cognate antigen when the variable regions of the antibody or fragment recognize and bind the cognate antigen with a detectable preference distingui shing the antigen from other known

polypeptides of similar but not identical sequence by virtue of measurable differences in binding affinity. It will be understood that antigen-specific antibodies and fragments may also interact with other proteins (for example, S. aureus protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the antibody or fragment. It is to be understood that interaction of the MAGEA3 binding antibodies or binding fragments thereof with Protein A or G is not considered as an antigen-specific interaction. Screening assays to determine binding specificity of an antibody are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow et al. (Eds), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), Chapter 6. As the MAGEA3 contemplated in the context of the present invention are typically only expressed in tumor tissue or immune privileged tissue, specific binding antibodies or fragments thereof will preferably detectably bind (as judged by common assays) in tumor tissue to MAGEA3 only, but not to other polypeptides which are expressed both in tumor tissue and normal tissue.

However, MAGEA3 is a member of the MAGEA family and shares significant homology with at least some of the other members of the MAGEA family such as MAGEA6 (about 96% homology) or MAGEA2 (about 84% homology). The homology with other family members such as MAGEA1 and MAGEA4 (about 68% homology) or MAGEA 10 (about 50% homology) is lower.

While MAGE A3 binding antibodies or binding fragments thereof will usual ly be specific in the sense that they bind MAGEA3 stronger than e.g. other members of the MAGEA family, the MAGEA3 binding antibodies or binding fragments thereof may also bind to MAGEA6 and in particular human MAGEA6 given that it shares 96% sequence identity with MAGE A3. A MAGEA3 binding antibody or binding fragment as described herein may therefore also be designated as a MAGEA6 binding antibody or binding fragment thereof. Given the high homology between MAGEA3 and MAGEA6, it is assumed that these proteins have similar if not identical roles e.g. in cancer development so that such a pan reactivity towards MAGEA3 and MAGEA6 may be of therapeutic advantage. The capability of MAG E A3 binding antibodies or binding fragments thereof in accordance with the invention to bind also to MAGEA6 does not preclude that these antibodies w ill bind stronger to MAGEA3 than MAGEA6. In some embodiments, MAGEA3 binding antibodies or binding fragments thereof may optionally not even bind to MAGEA6.

It has been observed that the expression pattern of MAGE A3 and other family members such as MAGEA 1 . MAGEA4 and MAGEA 10 can di ffer between cancer types, which may point to different roles of these proteins in cancer development and progression. In order to ensure that a pharmaceutically active MAGEA3 binding antibody or binding fragment thereof indeed only interferes w ith the function of MAG EA3, it can be preferred that the antibodies or binding fragments in accordance w ith the invention recognize only MAGEA3, but preferably not MAGEA4,

MAGEA 1 and. or MAGEA 1 0. Such antibodies are considered to preferentially bind MAG EA3. It is to be understood that the statement that a MAGEA3 binding antibody or binding fragment thereof does not bind e.g. MAG EA4 is based on experiments that are commonly used to determine the preference of antibody binding towards certain targets. To this extent, one may use for example El . IS A assays where different antigens such as MAGEA3, MAGEA4 etc. are coated on a substrate and subsequently binding of a particular antibody is tested. MAGEA3 binding antibodies and binding fragments thereof in accordance with the invention thus may not detectably bind to MAGEA 1 , MAGEA4 and MAGE 10 over a negative control antibody as can be determined e.g. in common EL ISA or Western Blot assays. This is illustrated e.g. for the exemplary antibody 2 1 B4 in the example section w hich shows preferential specificity for MAGE A3 over MAGEA 1 , MAGEA4 and

MAGE 10. MAGEA3 binding antibodies and binding fragments thereof in accordance with the invention may thus prefential ly bind to MAGE A3 over

MAGEA 1 , MAGEA4 and MAGE 1 0 if compared with the mouse monoclonal antiboday M3H76, which is described e.g. in Chitaie et al.. Modern Pathology, 18, 1 19, 126 ( 2005 ).

In some embodiments the present invention thus relates to MAGEA3 binding antibodies or binding fragments thereof which preferentially bind to MAG E A3 and thus do not bind to MAGEA4, MAGEAl , MAGEA 10 and. or optionally even MAGEA2.

Antibodies or binding fragments thereof, regardless of whether they are MAG E A3 binding antibodies or binding fragments thereof or e.g. the other antibodies described herein such as the anti-CD40 agonistic antibodies may have an equilibrium

dissociation constant (K_D) for the binding of the antibody (or the binding fragment thereof) to its antigen in the low nanomolar to low picomo!ar or even in the subpicomolar range (avidity). Thus the K|> may be in the range of about 0. 1 * 10 ¹ to about 1 * 10 \ preferably in the range of about 0.1 * 10^~12 to about 0. 1 * 10^" , more preferably in the range of about 0. 1 * 10 ^{1 2} to about 10* 10 \ even more preferably in the range of about 0. 1 * 10 ' to about 1 * 10 \ The most preferred KDs may be in the range of about 0. 1 * 10 ¹ to about 0. 1 * 10^"9, in the range of about 0. 1 * 1 0 ¹ to about 10* 10 ¹ or in the range of about 0. 1 * 10 ¹ to about 1 * 10 ^{1 2} such as about 0.9* 1 0 ¹ \ about 0.8* 1 0 ' \ about 0.7* 10 ' about 0.6* 1 0 ^{1 2} or about 0.5* 10 ^{1 2}. Thus MAGEA3 binding antibodies or binding fragments thereof as described hereinafter may have a Ki) of about 300 pM or less, about 200 pM or less, about 100 pM or less, about 90 pM or less, about 80 pM or less, about 70 pM or less, about 60 pM or less, about 50 pM or less, about 40 pM or less, about 30 pM or less about 20 pM or less. Even lower Kj s may be achievable by optimization of CDRs.

The Ki) is usually considered to be a measure for the affinity of an interaction between two molecules. Strictly speaking, affinity describes the strength of binding o a molecule to another molecule at a single site. However, an antibody usual ly has two binding sites for an antigen. The strength of this interaction is usually considered to be the avidity.

In the context of the present invention, the term "affinity" is used to describe both the strength of the interaction of e.g. a monovalent scFv to its antigen as well as the binding of a typical divalent antibody to its antigen. D values and thus the affinity avidity of the antibodies or binding fragments thereof can be determined making use of established approaches in the art.

Another measure of the affinity of an antibody such as the MAGEA3 binding antibodies or binding fragments described herein towards their antigen is the EC50 concentration. Antibodies or binding fragments thereof, regardless of whether they are MAGEA3 binding antibodies or binding fragments thereof or e.g. the other antibodies described herein such as the anti-CD40 agonistic antibodies may have an EC50 for the binding of the antibody (or the binding fragment thereof) to its antigen in the low nanomolar to low picomolar or even in the subpicomolar range. Thus the EC50 may be in the range of about 0.1 * 10^~!2 to about 1 * 1 0 \ preferably in the range of about 0. 1 * 10 ^{1 2} to about 0. 1 * 1 0^"7, more preferably in the range of about 0. 1 * 1 0 ^{1 2} to about 10* 10^"'', even more preferably in the range of about 0.1 * 10 ^{1 2} to about 1 * 10^" ⁹. The most preferred EC50S may be in the range of about 0. 1 * 10 ^! to about 0.1 * 10^~9, in the range of about 0. 1 * 10 ^{1 3} to about 10* 10^" ' ^" or in the range of about 0. 1 * 10 ^{1 2} to about 1 * 10^"12 such as about 0.9* 1 0 ' \ about 0.8* 10^~12, about 0.7* 10 ' about 0.6* 10 ¹² or about 0.5* 1 0 ¹ . Thus MAGEA3 binding antibodies or binding fragments thereof as described hereinafter may have an EC50 of about 300 pM or less, about 200 pM or less, about 100 pM or less, about 90 pM or less, about 80 pM or less, about 70 pM or less, about 60 pM or less, about 50 pM or less, about 40 pM or less, about 30 pM or less about 20 pM or less. Even lower ECso's may be achievable by optimization of CDRs. The EC50 is determined as the concentration at which half-maximal binding of the antibody to its antigen in El . IS A w as observed.

The antibodies and binding fragments thereof as they are used in the context of the present invention, i.e. regardless of w hether they are MAGE A3 binding antibodies or binding fragments thereof or e.g. the other antibodies described herein such as the anti-CD40 agonistic antibodies as mentioned hereinafter may be preferably monoclonal chimeric, humanized or human antibodies. These antibodies are preferably of the IgG class.

At least for the MAGE A3 binding antibodies or binding fragments thereof it can be preferred to use monoclonal human antibodies. Such antibodies are preferably

"patient-derived". A "patient-derived" human monoclonal antibody refers to an antibody which has been obtained from a patient suffering from a tumor expressing a TAA as defined above and in particular MAGEA3 and/or MAGEA6. In some embodiments, it can be preferred to isolate such antibodies from patients w hich suffer from a tumor expressing a TAA as defined above and in particular MAGE A3 and/or MAGEA6 and display a favorable clinical course of disease. Such favorable clinical course of disease may become apparent e.g. from quality of life, overal l survival, improved time to progression and/or improved REC1ST criteria. RECIST ("Response

Evaluation Criteria In Sol id Tumors") is e.g. use to determine whether a patient has shown a complete or at least partial response to treatment of such tumor. An explanat ion and overvie of these criteria can be found inter alia at Eisenhauer et al., (2009) European Journal of Cancer, 228-247 or at http://www.eortc.be/recist/ and are incorporated by reference.

It is to be understood that a favorable clinical course of disease may be observed in patients which have been diagnosed with a tumor and w hich e.g. have received non- specific chemotherapy and/or vaccination with a CT antigen such as MAGE A3. A patient which has shown a favorable clinical course of disease, may be eligible for isolation and identification of MAGEA3 binding antibodies even if the patient which has been diagnosed w ith a tumor, has not been e.g. vaccinated with a MAGE A3 antigen.

The use of such patient-derived antibodies is assumed to prov ide for at least comparable efficacy even if they are administered to patients different from the ones from which they have been isolated. For example, the specific MAGEA3 binding antibodies or binding fragments thereof mentioned herein have been isolated from patients, which have shown a favorable clinical response and have shown

spontaneous MAGEA3 binding antibodies. Such antibodies are e.g. assumed to be able to recruit CD4 , CDS ^' cytotoxic T cells into xenografted tumors of mice and also to tumors of patients w hich express MAGEA3 and/or MAGEA6.

A patient-derived human monoclonal antibody can be assumed to show efficacy also in other human patients which suffer from a hyperproliferative disease such as a cancer being characterized by MAGE A3 and/or MAGEA6 overexpression given that it has been isolated from a patient which has shown a favorable cl inical course of disease as mentioned above. These antibodies have a fully human sequence and thus should pose no problem e.g. with respect to immunogenieity.

Some examples of such patient derived human monoclonal MAGEA3 binding antibodies include 21B4, 31H10, 54B4, 43 B I O, 94G 1 1 , 9A5, 26C9, 20C10, 2G4 or 4D6.

The variable heavy chain of 21B4 is e.g. encoded by SEQ ID No. 1. The variable l ight chain of 2 1 B4 is e.g. encoded by SEQ ID No. 2. The variable heavy chain of 2 1 b4 thus has an amino acid sequence of SEQ ID No. 3. The variable light chain of 2 1 B4 thus has an amino acid sequence of SEQ I D No. 4. As regards the variable heavy chain of 21B4, the CDR1 has an amino acid sequence of SEQ ID No. 5, the CDR2 has an amino acid sequence of SEQ ID No. 6 and the CDR3 has an amino acid sequence of SEQ I D No. 7. As regards the variable light chain of 2 1 B4, the

CDR1 has an amino acid sequence of SEQ ID No. 8, the CDR2 has an amino acid sequence of SEQ ID No. 9 and the CDR3 has an amino acid sequence of SEQ ID No. 10.

The variable heavy chain of 3 1 H 10 is e.g. encoded by SEQ ID No. 1 1. The variable light chain of 31H10 is e.g. encoded by SEQ ID No. 12. The variable heavy chain of 31H10 thus has an amino acid sequence of SEQ ID No. 13. The variable light chain of 31H10 thus has an amino acid sequence of SEQ ID No. 14. As regards the variable heavy chain of 31H10, the CDR1 has an amino acid sequence of SEQ ID No. 15, the CDR2 has an amino acid sequence of SEQ I D No. 1 6 and the CDR3 has an amino acid sequence of SEQ I D No. 17. As regards the variable light chain of 31H10, the CDR1 has an amino acid sequence of SEQ I D No. 18, the CDR2 has an amino acid sequence of SEQ ID No. 19 and the CDR3 has an amino acid sequence of SEQ I D No. 20.

The variable heavy chain of 54B4 is e.g. encoded by SEQ ID No. 2 1 . The variable light chain of 54B4 is e.g. encoded by SEQ I D No. 22. The variable heavy chain of

54B4 thus has an amino acid sequence of SEQ ID No. 23. The variable light chain of 54B4 thus has an amino acid sequence of SEQ ID No. 24. As regards the variable heavy chain of 54B4, the CDR1 has an amino acid sequence of SEQ ID No. 25, the CDR2 has an amino acid sequence of SEQ ID No. 26 and the CDR3 has an amino acid sequence of SEQ I D No. 27. As regards the variable light chain of 54B4, the CDR1 has an amino acid sequence of SEQ ID No. 28, the CDR2 has an amino acid sequence of SEQ ID No. 29 and the CDR3 has an amino acid sequence of SEQ ID No. 30. The variable heavy chain of 43B10 is e.g. encoded by SEQ ID No. 31. The variable l ight chain of 43 B i 0 is e.g. encoded by SEQ I D No. 32. The variable heavy chain of 43B 1 0 thus has an amino acid sequence of SEQ ID No. 33. The variable l ight chain of 43 B I O thus has an amino acid sequence of SEQ I D No. 34. As regards the variable heavy chain of 43B 10, the CDRi has an amino acid sequence of SEQ ID No. 35, the CDR2 has an amino acid sequence of SEQ I D No. 36 and the CDR.3 has an amino acid sequence of SEQ ID No. 37. As regards the variable light chain of 43 B I O, the CDRI has an amino acid sequence of SEQ ID No. 38, the CDR2 has an amino acid sequence of SEQ ID No. 39 and the CDR3 has an amino acid sequence of SEQ ID No. 40.

The variable heavy chain of 94G1 1 is e.g. encoded by SEQ ID No. 41 . The variable light chain of 94G1 1 is e.g. encoded by SEQ I D No. 42. The variable heavy chain of 94 G 1 1 thus has an amino acid sequence of SEQ ID No. 43. The variable l ight chain of 94G1 1 thus has an amino acid sequence of SEQ I D No. 44. As regards the variable heavy chain of 94 G 1 1 , the CDRI has an amino acid sequence of SEQ I D No. 45, the CDR2 has an amino acid sequence of SEQ I D No. 46 and the CDR3 has an amino acid sequence of SEQ I D No. 47. As regards the variable light chain of 94G 1 1 , the CDRI has an amino acid sequence of SEQ I D No. 48, the CDR2 has an amino acid sequence of SEQ ID No. 49 and the CDR3 has an amino acid sequence of SEQ I D No. 50.

The variable heavy chain of 9A5 is e.g. encoded by SEQ ID No. 51. The variable light chain of 9A5 is e.g. encoded by SEQ I D No. 52. The variable heavy chain of 9A5 thus has an amino acid sequence of SEQ ID No. 53. The variable light chain of 9A5 thus has an amino acid sequence of SEQ ID No. 54. As regards the variable heavy chain of 9A5, the CDR I has an amino acid sequence of SEQ ID No. 55. the CDR2 has an amino acid sequence of SEQ ID No. 5 and the CDR3 has an amino acid sequence of SEQ I D No. 57. As regards the variable l ight chain of 9A5, the CDR I has an amino acid sequence of SEQ ID No. 58, the CDR2 has an amino acid sequence of SEQ ID No. 59 and the CDR3 has an amino acid sequence of SEQ I D No. 60.

The variable heavy chain of 26C9 is e.g. encoded by SEQ I D No. 6 1 . The variable light chain of 26C9 is e.g. encoded by SEQ I D No. 62. The variable heavy chain of 26C9 thus has an amino acid sequence of SEQ I D No. 63. The variable l ight chain of 26C9 thus has an amino acid sequence of SEQ I D No. 64. As regards the variable heavy chain of 26C9, the CDR.1 has an amino acid sequence of SEQ ID No. 65, the CDR2 has an amino acid sequence of SEQ ID No. 66 and the CDR3 has an amino acid sequence of SEQ I D No. 67. As regards the variable light chain of 26C9, the CDR.1 has an amino acid sequence of SEQ I D No. 68, the CDR2 has an amino acid sequence of SEQ ID No. 69 and the CDR3 has an amino acid sequence of SEQ ID No. 70. The variable heavy chain of 20C10 is e.g. encoded by SEQ I D No. 7 1 . The variable l ight chain of 20C10 is e.g. encoded by SEQ I D No. 72. The variable heavy chain of 20C10 thus has an amino acid sequence of SEQ I D No. 73. The variable light chain of 20C10 thus has an amino acid sequence of SEQ I D No. 74. As regards the variable heavy chain of 20C10, the CDR1 has an amino acid sequence of SEQ I D No. 75, the CDR2 has an amino acid sequence of SEQ I D No. 76 and the CDR3 has an amino acid sequence of SEQ I D No. 77. As regards the variable light chain of 20C10, the CDR1 has an amino acid sequence of SEQ I D No. 78, the CDR2 has an amino acid sequence of SEQ I D No. 79 and the CDR3 has an amino acid sequence of SEQ I D No. 80.

The variable heavy chain of 2G4 is e.g. encoded by SEQ I D No. 8 1 . The variable light chain of 2G4 is e.g. encoded by SEQ I D No. 82. The variable heavy chain of 2G4 thus has an amino acid sequence of SEQ ID No. 83. The variable light chain of 2G4 thus has an amino acid sequence of SEQ I D No. 84. As regards the variable heavy chain of 2G4, the CDR1 has an amino acid sequence of SEQ I D No. 85, the CDR2 has an amino acid sequence of SEQ ID No. 86 and the CDR3 has an amino acid sequence of SEQ ID No. 87. As regards the variable light chain of 2G4, the CDR1 has an amino acid sequence of SEQ ID No. 88, the CDR2 has an amino acid sequence of SEQ ID No. 89 and the CDR3 has an amino acid sequence of SEQ ID No. 90.

The variable heavy chain of 4D6 is e.g. encoded by SEQ ID No. 91 . The variable light chain of 4D6 is e.g. encoded by SEQ I D No. 92. The variable heavy chain of 4D6 thus has an amino acid sequence of SEQ ID No. 93. The variable light chain of 4D6 thus has an amino acid sequence of SEQ ID No. 94. As regards the variable heavy chain of 4D6, the CDR1 has an amino acid sequence of SEQ ID No. 95, the CDR2 has an amino acid sequence of SEQ ID No. 96 and the CDR3 has an amino acid sequence of SEQ I D No. 97. As regards the variable light chain of 4D6, the CDR1 has an amino acid sequence of SEQ ID No. 98, the CDR2 has an amino acid sequence of SEQ ID No. 99 and the CDR3 has an amino acid sequence of SEQ ID No. 1 00.

As the specificity and affinity of an antibody is largely determined by its variable heavy chain and light chain sequences and in particular by the CDRs thereof, it can, be assumed that these properties are maintained even if the variable heavy chain and light chain sequences or CDRs thereof of human, patient-derived antibodies are transferred into other backbones. The present invention therefore also relates to MAGE3 binding antibodies and binding fragments thereof, which make use of variable heavy chain and light chain sequences and in particular by the CDRs thereof derived from human patient-derived antibodies, which are e.g. monoclonal chimeric or humanized antibodies. It is in fact known that introducing e.g. mouse-derived amino acids in framework positions of otherwise fully human antibodies may e.g. improve the ADCC response. Rules for selecting such modifications may e.g. be taken from e.g. EP 0 451 2 16. It is also know n that once, a CDR or set of CDRs has been identified, it is possible to perform e.g. conservative amino acid substitutions in the CDR(s), while maintaining the affinity and/or specificity of an antibody. Such substitutions, which preferably are conservative, i.e. replacement by an amino acid with another amino acid with comparable physico-chemical properties (e.g. Ala by Leu, or Glu by Asp), but do not necessarily have to be conservative, can be identified by changing amino acids in the CDRs and/or framework regions and then testing the modified antibody vs. the original antibody for its antigen binding using e.g.

BIACORE measurements.

Examples of MAGEA3 binding antibodies or binding fragments thereof therefore include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and. or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDR1 selected from SEQ ID Nos.: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 9, 19, 29, 39, 49, 59, 69, 79, 89, 99 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ I D Nos.: 1 0, 20, 30, 40, 50, 60, 70, 80, 90, 100 or sequences at least 80% identical thereto; and/or wherein

b) the heavy chain variable region comprises at least a CDR1 selected from SEQ I D Nos.: 5, 1 5, 25, 35. 45, 55, 65, 75, 85, 95 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96 or sequences at least 80%> identical thereto, and/or a CDR3 selected from SEQ ID Nos.: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97 or sequences at least 80% identical thereto. Other examples of MAGE A3 binding antibodies or binding fragments thereof include monoclonal ant ibodies or binding fragments thereof comprising a light chain v ariable region and/or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDR1 selected from SEQ ID Nos.: 8 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 9 or sequences at least 80% identical thereto, and/or a CDR.3 selected from SEQ ID Nos.: 10 or sequences at least 80% identical thereto; and/or wherein

b) the heavy chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 5 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ ID Nos. : 7 or sequences at least 80%o identical thereto.

Other examples of MAGEA3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and. or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 18 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 1 9 or sequences at least 80% identical thereto, and. or a CDR3 selected from SEQ I D Nos.: 20 or sequences at least 80% identical thereto; and/or wherein

b) the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 15 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ I D Nos.: 16 or sequences at least 80% identical thereto, and/or a CDR.3 selected from SEQ I D Nos.: 17 or sequences at least 80%> identical thereto.

Other examples of MAGEA3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and/or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 28 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 29 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ I D Nos.: 30 or sequences at least 80%> identical thereto: and. or wherein b) the heavy chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 25 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 26 or sequences at least 80% identical thereto, and. or a CDR.3 selected from SEQ I D Nos.: 27 or sequences at least 80%o identical thereto.

a) the light chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 38 or sequences at least 80%o identical thereto, a CDR2 selected from SEQ I D Nos.: 39 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ ID Nos.: 40 or sequences at least 80%o identical thereto; and. or wherein

b) the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 35 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ I D Nos.: 36 or sequences at least 80% identical thereto, and. or a CDR3 selected from SEQ I D Nos.: 37 or sequences at least 80%> identical thereto.

a) the light chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 48 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 49 or sequences at least 80%> identical thereto, and. or a CDR3 selected from SEQ I D Nos.: 0 or sequences at least 80%> identical thereto; and/or wherein

b) the heavy chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 45 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 46 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ ID Nos.: 47 or sequences at least 80% identical thereto.

a) the light chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 58 or sequences at least 80% identical thereto, a CDR2 selected from. SEQ I D Nos.: 59 or sequences at least 80% identical thereto, and. or a CDR3 selected from SEQ I D Nos.: 60 or sequences at least 80% identical thereto; and. or wherein

b) the heavy chain variable region comprises at least a CDR l selected from SEQ I D Nos.: 55 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 5 or sequences at least 80% identical thereto, an d or a CDR3 selected from SEQ I D Nos.: 57 or sequences at least 80% identical thereto.

Other examples of MAGE A3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and/or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 68 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 69 or sequences at least 80% identical thereto, and or a CDR3 selected from SEQ I D Nos.: 70 or sequences at least 80% identical thereto; and or w herein

b) the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 65 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos. : 66 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ I D Nos.: 67 or sequences at least 80% identical thereto. Other examples of MAGE A3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDR l selected from SEQ ID Nos.: 78 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 79 or sequences at least 80% identical thereto, and or a CDR3 selected from SEQ I D Nos.: 80 or sequences at least 80% identical thereto; and. or wherein

b) the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 75 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 76 or sequences at least 80% identical thereto, and, or a CDR3 selected from SEQ I D Nos.: 77 or sequences at least 80% identical thereto.

Other examples of MAGE A3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain v ariable region and/or a heavy chain variable region, wherei

a) the light chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 88 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 89 or sequences at least 80% identical thereto, and/or a CDR.3 selected from SEQ I D Nos.: 90 or sequences at least 80% identical thereto; and/or wherein

b) the heavy chain variable region comprises at least a CDR l selected from SEQ I D Nos.: 85 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos. : 86 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ I D Nos.: 87 or sequences at least 80% identical thereto. Other examples of MAGE A3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I Nos.: 99 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ I Nos.: 100 or sequences at least 80% identical thereto; and, or wherein

b) the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 95 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 96 or sequences at least 80% identical thereto, and/or a CDR.3 selected from SEQ I D Nos.: 97 or sequences at least 80% identical thereto.

a) the light chain variable region comprises at least a CDR l selected from SEQ I D Nos.: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 9, 1 9, 29, 39, 49, 59, 69, 79. 89, 99 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 10. 20, 30, 40, 50, 60, 70, 80, 90, 100 or sequences at least 80% identical thereto; and/or wherein

b) the heavy chain variable region comprises at least a CDR l selected from SEQ I D Nos.: 5, 15, 25, 35, 45, 55, 65, 75, 85, 95 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos. : 7, 17. 27. 37, 47, 57, 67, 77. 87, 97 or sequences at least 80% identical thereto. Other examples of MAGE A3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDR1 selected from SEQ ID Nos.: 8 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 9 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 10 or sequences at least 80% identical thereto; and/or wherein

b) the heavy chain variable region comprises at least a CDR1 selected from SEQ ID Nos.: 5 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 7 or sequences at least 80%> identical thereto.

a) the light chain variable region comprises at least a CDR1 selected from SEQ ID Nos.: 18 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 19 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 20 or sequences at least 80% identical thereto; and/or wherein

b) the heavy chain variable region comprises at least a CDR1 selected from SEQ ID Nos.: 15 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 16 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 17 or sequences at least 80%> identical thereto.

Other examples of MAGEA3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and. or a heavy chain variable region, wherein the light chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 28 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 29 or sequences at least 80% identical thereto, and a CDR3 selected from. SEQ ID Nos.: 30 or sequences at least 80% identical thereto; and or wherein

the heavy chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 25 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ ID Nos.: 26 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ I D Nos.: 27 or sequences at least 80%> identical thereto.

a) the light chain variable region comprises at least a DR l selected from SEQ ID Nos.: 38 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ ID Nos.: 39 or sequences at least 80%> identical thereto, and a CDR3 selected from SEQ ID Nos.: 40 or sequences at least 80%o identical thereto; and. or wherein

b) the heavy chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 35 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ ID Nos.: 36 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 37 or sequences at least 80%> identical thereto.

a) the light chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 48 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ ID Nos.: 49 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 50 or sequences at least 80% identical thereto; and/or wherein

the heavy chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 45 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 46 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 47 or sequences at least 80% identical thereto. Other examples of MAGEA3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 58 or sequences at least 80%o identical thereto, a CDR2 selected from SEQ I D Nos.: 59 or sequences at least 80% identical thereto, and a

CDR3 selected from SEQ ID Nos.: 60 or sequences at least 80%> identical thereto; and. or wherein

b) the heavy chain variable region comprises at least a CDR l selected from SEQ ID Nos.: 55 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 56 or sequences at least 80% identical thereto, and a

CDR3 selected from SEQ I D Nos.: 57 or sequences at least 80%> identical thereto.

Other examples of MAGEA3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and. r a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 68 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ ID Nos.: 69 or sequences at least 80%> identical thereto, and a CDR3 selected from SEQ ID Nos.: 70 or sequences at least 80% identical thereto; and or wherein

b) the heavy chain variable region comprises at least a CDR l selected from SEQ I D Nos.: 65 or sequences at least 80% identical thereto, a CDR2 selected from SEQ I D Nos.: 66 or sequences at least 80% identical thereto, and a

CDR3 selected from SEQ ID Nos.: 67 or sequences at least 80% identical thereto.

Other examples of MAGEA.3 binding antibodies or binding fragments thereof include monoclonal antibodies or binding fragments thereof comprising a light chain variable region and/or a heavy chain variable region, wherein

a) the light chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 78 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 79 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ I D Nos.: 80 or sequences at least 80%> identical thereto; and. or wherein

b) the heavy chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 75 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ ID Nos.: 76 or sequences at least 80% identical thereto, and a CDR.3 selected from SEQ ID Nos.: 77 or sequences at least 80% identical thereto.

a) the light chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 88 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ ID Nos.: 89 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 90 or sequences at least 80%> identical thereto; and/or wherein b) the heavy chain variable region comprises at least a CDR1 selected from SEQ ID Nos.: 85 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 86 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ I D Nos.: 87 or sequences at least 80% identical thereto.

a) the light chain variable region comprises at least a CDR1 selected from SEQ ID Nos.: 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 99 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 100 or sequences at least 80%> identical thereto; and. or wherein

b) the heavy chain variable region comprises at least a CDR1 selected from SEQ ID Nos.: 95 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ I D Nos.: 96 or sequences at least 80%> identical thereto, and a CDR3 selected from SEQ I D Nos.: 97 or sequences at least 80%> identical thereto.

Preferably, in ail these embodiments the sequence identity is at least about 85%, more preferably at least about 90%, even more preferably at least about 95% and most preferably at least about. 96%>, 97%>, 98 > or about 99%>. Sequence identity may be determined over the whole length of the respective sequences.

The determination of percent identity between two sequences is preferably

accompl ished using the mathematical algorithm of Karl in and Altschul ( 1993 ) Proc. Natl. Acad. Sci USA 90: 5873-5877. Such an algorithm is incorporated into the BLASTn and BLASTp programs of Altschul et al. (1990) J. Mol. Biol. 215: 403-410 available at NCBI (http://www.ncbi.nim.nih.gov/blast Biast.cge). The determination of percent identity is performed with the standard parameters of the BLASTn and BLASTp programs. BLAST polynucleotide searches are performed with the BLASTn program.

For the general parameters, the "Max Target Sequences" box may be set to 100, the "Short queries^" box may be ticked, the "Expect threshold^" box may be set to 10 and the "Word Size" box may be set to 28. For the scoring parameters the

"Match/mismatch Scores" may be set to 1 ,-2 and the "Gap Costs^" bo may be set to linear. For the Filters and Masking parameters, the "Low complexity regions" box may not be ticked, the "Species-specific repeats" box may not be ticked, the "Mask for lookup table only" box may be ticked, and the "Mask lower case letters" box may not be ticked. BLAST protein searches are performed with the BLASTp program. For the general parameters, the "Max Target Sequences" box may be set to 1 00, the "Short queries^" box may be ticked, the "Expect threshold^" box may be set to 10 and the "Word Size^" box may be set to "3". For the scoring parameters the "Matrix" box may be set to "BLOSUM62", the "Gap Costs" Box may be set to "Existence: 1 1 Extension: !.", the "Compositional adjustments^" box may be set to "Conditional compositional score matrix adjustment^". For the Filters and Masking parameters the "Low complexity regions" box may not be ticked, the "Mask for lookup table only" box may not be ticked and the "Mask lower case letters^" box may not be ticked. The above-ment ioned CDRs of a light and heavy chain variable region are preferably embedded in the framework and constant region of a human-derived antibody, i.e. in the sequences as determined for antibodies obtained from human patients as described herein. Preferably these antibodies are of the IgG class. However, the above-mentioned CDRs of a light and heavy chain variable region may also be embedded in human sequences of framework and constant regions derived from other human antibodies, particularly if such sequences have been shown to be effective in antibody dependent cel l mediated cytotoxicity (ADCC). In this context, one may e.g. use the human constant and framework sequences of humanized therapeutic antibodies that have been successfully used for therapeutic applications. The above-ment ioned CDRs of a light and heavy chain variable region are preferably incorporated into the framework and constant regions of such humanized antibodies of the human IgG class.

Further, the above-mentioned DRs of a light and heavy chain variable region may be embedded in essentially human sequences for framework and constant regions. However, particularly the framework regions, but also the constant regions may- comprise amino acids as they are e.g. typically found in mouse antibodies which are known to enhance antigen binding and/or e.g. ADCC (see e.g. European patent appl ication EP 0 451 216). Preferably these antibodies are of the IgG class.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D Nos.: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and. or a heavy chain variable region comprising SEQ ID Nos. : 3, 13, 23, 33, 43, 53, 63, 73,83, 93 or sequences at least 80% identical thereto.

Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D Nos.: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 3, 1 3. 23, 33. 43, 53. 63, 73.83, 93 or sequences at least 80%o identical thereto. Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ ID No. : 4 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 3, 13, 23, 33, 43, 53, 63, 73.83. 93 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof compri sing a light chain variable region comprising SEQ ID No.: 14 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 3, 13, 23, 33, 43, 53, 63, 73,83, 93 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ ID No.: 24 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 3, 13, 23, 33, 43, 53, 63. 73,83, 93 or sequences at least 80% identical thereto.

Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D No.: 34 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ 1 D Nos.: 3, 1 3, 23. 33, 43. 53, 63. 73,83. 93 or sequences at least 80% identical thereto. Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D No.: 44 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 3, 13, 23. 33, 43. 53. 63, 73,83, 93 or sequences at least 80% identical thereto. Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ ID No. : 54 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 3, 13, 23, 33, 43, 53, 63, 73,83, 93 or sequences at least 80% identical thereto.

Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof compri sing a light chain variable region compri sing SEQ I D No.: 64 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 3, 13, 23, 33, 43, 53, 63, 73,83, 93 or sequences at least 80% identical thereto.

Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ ID No. : 74 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 3, 1 , 23, 33, 43, 53, 63, 73,83, 93 or sequences at least 80% identical thereto.

Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ ID No.: 84 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 3, 13, 23, 33, 43, 53, 63, 73,83, 93 or sequences at least 80% identical thereto. Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D No.: 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 3. 1 , 23, 33, 43. 53, 63, 73,83, 93 or sequences at least 80% identical thereto. Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ ID Nos.: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 3 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a l ight chain variable region comprising SEQ I D Nos.: 4, 14, 24, 34, 44. 54. 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 13 or sequences at least 80% identical thereto.

Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D Nos.: 4, 14, 24, 34. 44. 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 23 or sequences at least 80% identical thereto.

Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D Nos.: 4, 14. 24, 34, 44, 54. 64, 74. 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 33 or sequences at least 80% identical thereto. Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D Nos.: 4. 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 43 or sequences at least 80% identical thereto. Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ ID Nos.: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 53 or sequences at least 80% identical thereto.

Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a l ight chain variable region comprising SEQ I D Nos.: 4, 14, 24, 34, 44, 54. 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 63 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D Nos.: 4. 14, 24, 34, 44, 54. 64, 74. 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 73 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a l ight chain variable region comprising SEQ I D Nos.: 4, 14, 24, 34. 44, 54. 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 83 or sequences at least 80% identical thereto. Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D Nos.: 4. 14, 24, 34. 44, 54. 64, 74. 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 93 or sequences at least 80% identical thereto. Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ ID Nos.: 4 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 3 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I Nos.: 14 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 33 or sequences at least 80% identical thereto.

Other MAGEA3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a l ight chain variable region comprising SEQ I D Nos.: 24 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 23 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a l ight chain variable region comprising SEQ I D Nos.: 34 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 33 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a l ight chain variable region comprising SEQ I D Nos.: 44 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos. : 43 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D Nos.: 54 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 53 or sequences at least 80% identical thereto. Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ ID Nos.: 64 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 63 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a l ight chain variable region comprising SEQ I D Nos.: 74 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos. : 33 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a l ight chain variable region comprising SEQ I D Nos.: 84 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos. : 83 or sequences at least 80% identical thereto.

Other MAGE A3 binding antibodies and binding fragments relate to antibodies or binding fragments thereof comprising a light chain variable region comprising SEQ I D Nos.: 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos. : 93 or sequences at least 80% identical thereto.

Preferably, in all these embodiments the sequence identity is at least about 85%, more preferably at least about 90%, even more preferably at least about 95% and most preferably at least about 98% or at least about 99%. Sequence identity is determined as described above. Sequence identity may be determined over the whole length of the respective sequence.

The above-mentioned light and heavy chain variable regions are preferably embedded in the constant regions of a human-derived antibody, i.e. in the sequences as determined for antibodies obtained from human patients as described herein. Preferably these antibodies are of the IgG class such as the IgG 1 class.. However, the above-mentioned l ight and heavy chain variable regions may also be embedded in human sequences of constant regions derived from other human antibodies, particularly if such sequences have been shown to be effective in ADCC. In this context, one may e.g. use the human constant sequences of humanized therapeutic antibodies that have been successfully used for therapeutic applications. The above-mentioned light and heavy chain variable regions are preferably incorporated into the constant regions of such humanized antibodies of the human IgG class. Further, the above-mentioned l ight and heavy chain variable regions may be embedded in essentially human sequences for constant regions. However, the constant regions may comprise amino acids as they are e.g. typically found in mouse antibodies, which are known to enhance ADCC. Preferably these antibodies are of the IgG class.

The MAGEA3 binding antibodies or binding fragments in accordance with the invention may bind to epitope(s) comprised within SEQ I D No. 102, SEQ I D No. 103 and/or SEQ I D No. 1 04. Preferably, the MAGE A3 binding antibodies or binding fragments in accordance with the invention may bind to epitope(s) comprised within S Q ID No. 105, SEQ I D No. 106 and/or SEQ I D No. 107.

The MAGEA3 binding antibodies or binding fragments thereof in accordance with the invention may bind to a three-dimensional epitope formed by sequences comprised within SEQ I D No. 105. SEQ I D No. 106 and SEQ ID No. 1 07.

Also preferably, the MAGEA3 binding antibodies or binding fragments in accordance with the invention may bind to epitope(s) comprised ithin SEQ ID No. 108. The invention also contemplates using MAGEA3 binding antibodies and binding fragments thereof binding substantial ly to the same epitope or parts of the same epitope as do the MAGE A3 bindi g antibodies and binding fragments as described above

Further, the invention considers using MAGE A3 binding antibodies and binding fragments thereof competing with MAGEA3 binding antibodies and binding fragments thereof as described above for binding to MAGEA3 and preferably for binding to human MAGEA3.

Epitope mapping may be undertaken by producing different fragments of MAGE A3 and to then test these fragments for binding to antibodies or the binding fragments thereof. Binding may be measured using EL IS A. Binding may also be determined using Biacore®. One may also use commercially available peptide arrays such as PepSpot™ from JPT Peptide Technologies GmbH (Berlin, Germany), solutions offered by Pe t i des& E 1 ephant s, Nuthetal, Germany or proteomics-based mass spectrometry methods. Competition for binding to a particular antigen or epitope can be determined using assays known in the art. For example one may label an antibody in accordance with the invention and test for its binding to MAGEA3. Subsequently, one adds unlabeled 21B4 (or any other MAGEA3 binding antibody) and determines whether it affects binding of the labeled antibody, or binding of the labeled antibody is studied in presence or absence of various concentrations of such unlabeled

MAG EA3 binding antibody . Such label could be radioactive or fluorescent or other kinds of detectable label .

Competition for binding to a particular antigen or epitope is determined by a reduction in binding to antigen or epitope of at least about 50%, or at least about

70%, or at least about 80%, or at least about 90%, or at least about 95%, or at least about 99% or about 100% for the antibody in accordance with the invention. Binding may be measured using Biacore® equipment, various fluorescence detection

technologies (e.g. Fluorescence correlation spectroscopy, fluorescence cross- correlation, Fluorescence Lifetime measurements etc.) or various types of

radioimmunoassays or other assays used to follow antibody binding to a target molecule.

As mentioned above, the present invention considers MAGE A3 binding antibodies or binding fragments thereof. A full-length antibody includes a constant domain and a variable domain. The constant region need not be present in an antigen-binding fragment of an antibody.

Binding fragments may thus include portions of an intact full-length antibody, such as an antigen binding or variable region of the complete antibody. Examples of antibody fragments include Fab, F(ab')₂, Id and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); muitispecific antibody fragments such as bispecific, trispecific, and muitispecific antibodies (e.g., diabodies, triabodies, tetrabodies); minibodies; chelating recombinant antibodies; tribodies or bibodies; intrabodies; nanobodies; small modular i m m u nopli a rmace u ticals (SMIP), binding-domain immunoglobulin fusion proteins; camel ized antibodies; VHH containing antibodies; and any other polypeptides formed from antibody fragments. The skilled person is aware that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.

A Fab fragment consists of the VL, VH, CL and CHI domains. An F(ab')² fragment comprises two Fab fragments linked by a disulfide bridge at the hinge region. An Fd is the VH and CHI domains of a single arm of an antibody. An Fv fragment is the VL and VH domains of a single arm of an antibody.

Binding fragments also encompass monovalent or multivalent, or monomeric or multimeric (e.g. tetrameric), CDR-derived binding domains. The M A G E A b i n d i n g antibodies and binding fragments thereof may also encompass variants of the exemplary antibodies, binding fragments and sequences disclosed herein. Variants include peptides and polypeptides comprising one or more amino acid sequence substitutions, deletions, and/or additions that have the same or substantially the same affinity and specificity of epitope binding as one or more of the exemplary antibodies, fragments and sequences disclosed herein. Thus, variants include peptides and polypeptides comprising one or more amino acid sequence substitutions, deletions, and. or additions to the exemplary antibodies, fragments and sequences disclosed herein where such substitutions, deletions and. or additions do not cause substantial changes in affinity and specificity of epitope binding. For example, a variant of an antibody or fragment may result from one or more changes to an ant ibody or fragment comprising one or more of amino acid sequence of SEQ ID NOS: 3. 4 etc. or where the changed antibody or fragment has the same or substantially the same affinity and specificity of epitope binding as the starting sequence.

Antibodies or binding fragments thereof as far as they are generally referred to in the context of the present invention may also be part of larger immunoadhesion molecules, formed by covalent or non-covalent association of the antibody or antibody portion with e.g. one or more other proteins or peptides. Examples of such immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule ( Kipriyanov, S. ML, et al. ( 1995 ) Human Antibodies and Hybridomas 6:93- 101 ) and use of a cysteine residue, a marker pept ide and a C- terminal polyhistidine tag to make bivalent and biotinylated scFv molecules

( Kipriyanov , S. M., et al. ( 1 994 ) Mol Immunol 31 : 1047-1058). Antibodies and fragments comprising immunoadhesion molecules can be obtained using standard recombinant DNA techniques, as described herein. Preferred antigen binding portions are complete domains or pairs of complete domains. The binding antibodies and binding fragments of the present invention may also encompass domain antibody (dAb) fragments (Ward et al, Nature 341 :544-546, 1989), which consist of a VH domain. The antibodies and binding fragments of the present invention also encompass diabodies are bivalent antibodies in which VH and V[ domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see e.g.. EP 404,097; WO 93/1 1 161 ; Holliger et al, Proc. Natl. Acad. Sci. USA 90:6444-6448, 1993, and Poljak et al, Structure 2: 1 121-1 123, 1994). Diabodies can be bispeci fic or monospecific.

As mentioned the antibodies and binding fragments of the present invention also encompass single-chain antibody fragments (scFv). An scFv comprises an antibody heavy chain variable region (VH) operably linked to an antibody light chain variable region (VL) wherein the heavy chain variable region and the l ight chain variable region, together or individually, form a binding site. A scFv may comprise a VH region at the amino-terminal end and a Vj region at the carboxy-terminal end.

Alternatively, scFv may comprise a Υ region at the amino-terminal end and a VH region at the carboxy-terminal end. Furthermore, although the two domains of the Fv fragment, V L and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g.. Bird et al . (1988) Science 242:423-426; and Huston et al . (1988) Proc. Natl . Acad. Sci. USA 85:5879-5883).

A scFv may optionally further comprise a polypeptide l inker between the heavy chain variable region and the light chain variable region. Such polypeptide linkers generally comprise between 1 and 50 amino acids, alternatively between 3 and 12 amino acids, alternatively 2 amino acids. An example of a linker peptide for l inking heavy and light chains in a scFv comprises the 5 amino acid sequence Gly-Gly-Gly- Gly-Ser (SEQ ID NO:37). Other examples comprise one or more tandem repeats of this sequence (for example, a polypeptide comprising two to four repeats of Gly-Gly- Gly-Gly-Ser (SEQ ID NO:37)) to create l inkers. The antibodies and binding fragments of the present invention also encompass heavy- chain antibodies (HCAb). Exceptions to the H I ₂ structure of conventional antibodies occur in some isotypes of the immunoglobulins found in camel ids (camels, dromedaries and llamas; H a m ers-C a st erm a n et al, 1993 Nature 363: 446; Nguyen et al, 1998 J. Mol. Biol. 275: 413), wobbegong sharks (Nuttaii et al, Mol Immunol. 38:313-26, 2001), nurse sharks (Greenberg et al, Nature 374: 168-73, 1995; Roux et al, 1998 Proc. Nat. Acad. Sci. USA 95: 1 1804), and in the spotted rat fish (Nguyen, et al., "Heavy-chain antibodies in Cameiidae; a case of evolutionary innovation," 2002 Immunogenetics 54(1): 39-47). These antibodies can apparently form antigen-binding regions using only heavy chain variable region, in that these functional antibodies are dimers of heavy chains only (referred to as "heavy-chain antibodies" or "HCAbs"). Accordingly, some embodiments of the present antibodies and binding fragments may be heavy chain antibodies (HCAb) that specifically bind to the tumor-associated antigen. For example, heavy chain antibodies that are a class of IgG and devoid of light chains are produced by animals of the genus Cameiidae that includes camels, dromedaries and llamas (Hamers-Casterman et al., Nature 363:446-448 (1993)). HCAbs have a molecular weight of about 95 kDa instead of the about 160 kDa molecular weight of conventional IgG antibodies. Their binding domains consist only of the heavy-chain variable domains, often referred to as VHH to distinguish them from conventional VH. Muyldermans et al., J. Mol. Recognit. 12: 131-140 ( 1999). The variable domain of the heavy-chain antibodies is sometimes referred to as a nanobody ( Cortez-Retamozo et al., Cancer Research 64:2853-57, 2004). A nanobody l ibrary may be generated from an immunized dromedary as described in Conrath et al., (Antimicrob Agents Chemother 45: 2807-12, 2001) or using recombinant methods. Since the first constant domain (CHI) is absent (spl iced out during mRNA processing due to loss o a splice consensus signal ), the variable domain (V_HH) is immediately followed by the hinge region, the C and the CH3 domains (Nguyen et al., Mol. Immunol. 36:515-524 ( 1999); Woolven et al.. Immunogenetics 50:98-101 (1999)). Camelid VHH reportedly recombines with IgG2 and IgG3 constant regions that contain hinge, CH2, and CH3 domains and lack a CHI domain ( Hamers-Casterman et al., supra). For example, llama IgGl is a conventional (H₂L₂) antibody isotype in which V'H recombines with a constant region that contains hinge, CHI , CH2 and CH3 domains, whereas the llama IgG2 and IgG3 are heavy chain-only isotypes that lack CHI domains and that contain no light chains.

Although the HCAbs are devoid of light chains, they have an antigen-binding repertoire. The genetic generation mechanism of HCAbs is reviewed in Nguyen et al . Adv. Immunol 79:261-296 (2001 ) and Nguyen et al.. Immunogenetics 54:39-47 ( 2002 ). Sharks, including the nurse shark, display similar antigen receptor-containing single monomeric V -domains. Irving et al., J. Immunol . Methods 248:31-45 ( 2001 ); Roux et al., Proc. Natl. Acad. Sci. USA 95: 1 1804 (1998).

V'HHS comprise small intact antigen-binding fragments (for example, fragments that are about 1 5 kDa, 1 18-136 residues). Camelid VHH domains have been found to bind to antigen with high affinity (Desmyter et al. , J. Biol. Chem. 276:26285-90, 2001), with VHH affinities typically in the nanomolar range and comparable with those of Fab and scFv fragments. VHHS are highly soluble and more stable than the

corresponding derivatives of scFv and Fab fragments. VH fragments have been relatively difficult to produce in soluble form, but improvements in solubil ity and specific binding can be obtained when framework residues are altered to be more Vim-like. (See, for example, Reichman et al., J Immunol Methods 1999, 231 :25-38.) VHHS carry amino acid substitutions that make them more hydrophi! ic and prevent prolonged interaction with BiP ( Immunoglobul in heavy-chain binding protein).

which normally binds to the H-chain in the Endoplasmic Reticulum (ER ) during folding and assembly, until it is displaced by the L-chain. Because of the V_HHS' increased hydrophilicity, secretion from the ER is improved.

Functional VHHS may be obtained by proteolytic cleavage of HCAb of an immunized camel id, by direct cloning of VHH genes from B-ceils of an immunized cameiid resulting in recombinant VHHS, or from naive or synthetic libraries. VHHS with desired antigen specificity may also be obtained through phage display methodology. Using VHHS in phage display is much simpler and more efficient compared to Fabs or scFvs, since only one domain needs to be cloned and expressed to obtain a functional antigen-binding fragment. Muyldermans, Biotechnol. 74:277-302 (2001); Ghahroudi et al, FEBS Lett. 414:521-526 (1997); and van der Linden et at, J. Biotechnol. 80:261-270 (2000). Methods for generating antibodies having camei id heavy chains are also described in U.S. Patent Publication Nos. 20050136049 and 2005003742 1 . The binding antibodies and binding fragments thereof may also encompass any of the e.g. foregoing specifical ly mentioned amino acid sequences of the light or heavy chains with one or more conservative substitutions (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, or 15 conservative substitutions). One can determine the positions of an amino acid sequence that are candidates for conservative substitutions, and one can select synthetic and naturally-occurring amino acids that effect conservative substitutions for any particular amino acids. Consideration for selecting conservative substitutions include the context in which any particular amino acid substitution is made, the hydrophobicity or polarity of the side-chain, the general size of the side chain, and the pK. value of side-chains with acidic or basic character under physiological conditions. For example, lysine, arginine, and histidine are often suitably substituted for each other. As is known in the art, this is because all three amino acids have basic side chains, whereas the pK. value for the side-chains of lysine and arginine are much closer to each other (about 10 and 12) than to histidine (about 6). Similarly, glycine, alanine, valine, leucine, and isoleucine are often suitably substituted for each other, with the proviso that glycine is frequently not suitably substituted for the other members of the group. Other groups of amino acids frequently suitably substituted for each other include, but are not limited to, the group consisting of glutamic and aspartic acids; the group consisting of

phenylalanine, tyrosine, and tryptophan; and the group consisting of serine.

threonine, and, optionally, tyrosine.

By making conservative modifications to the amino acid sequence or corresponding modifications to the encoding nucleotides, one can produce antibodies or binding fragments thereof having functional and chemical characteristics similar to those of the exemplary antibodies and fragments disclosed herein.

The binding antibodies and binding fragments thereof as they are mentioned in the context of the present invention may encompass derivatives of the exemplary antibodies, fragments and sequences disclosed herein. Derivatives include polypeptides or peptides, or variants, fragments or derivatives thereof, which have been chemical ly modified. Examples include covalent attachment of one or more polymers, such as water soluble polymers, N-linked, or O-l inked carbohydrates, sugars, phosphates, and/or other such molecules such as detectable labels such as fiuorophores.

Label ing agents may be coupled either directly or indirectly to the antibodies or antigens of the invention. One example of indirect coupling is by use of a spacer moiety. Furthermore, the antibodies of the present invention can comprise a further domain, said domain being linked by covalent or noncovalent bonds. The linkage can be based on genetic fusion according to the methods known in the art and described above or can be performed by, e.g., chemical cross-linking as described in, e.g., international application WO 94/04686. The additional domain present in the fusion protein comprising the antibody of the invention may preferably be l inked by a flexible linker, advantageously a polypeptide linker, wherein said polypeptide linker comprises plural, hydrophil ic, peptide-bonded amino acids of a length sufficient to span the distance between the C-terminal end of said further domain and the N- terminal end of the antibody of the invention or vice versa. The therapeutically or diagnostically active agent can be coupled to the antibody of the invention or an ant igen-binding fragment thereof by various means. This includes, for example, single-chain fusion proteins comprising the variable regions of the antibody of the invention coupled by covalent methods, such as peptide linkages, to the

therapeutically or diagnostically active agent. Further examples include molecules, which comprise at least an antigen-binding fragment coupled to additional molecules covalently, or non-covalently include those in the following non-limiting illustrative list. Traunecker et al .. Int. J. Cancer Surp. SuDP 7 ( 1 992 ), 5 1 -52, describes the bispecific reagent janusin in which the Fv region directed to CD3 is coupled to soluble CD4 or to other ligands such as OVCA and I L-7. Similarly an Fv region directed to MAGE A3 may be coupled to portions of e.g. an anti-CD40 agonistic antibody and or portions of an anti-CTLA4 antagonistic antibody. Similarly, the variable regions of the antibody of the invention can be constructed into Fv molecules and coupled to alternative l igands such as those illustrated in the cited article. H iggins et al ., J. Infect Disease 166 ( 1 992 ), 198-202, described a hetero- conjugated antibody composed of OK.T3 cross-linked to an antibody directed to a specific sequence in the V3 region of GP120. Such hetero-con jugate antibodies can also be constructed using at least the variable regions contained in the antibody of the invention methods. Additional examples of specific antibodies include those described by Fanger et al .. Cancer Treat. Res. 68 (1993), 181-194 and by Fanger et al ., Crit. Rev. Immunol. 12 ( 1992 ), 101 - 124. Conjugates that are immunotox ins including conv entional antibodies have been widely described in the art. The toxins may be coupled to the antibodies by conventional coupling techniques or

immunotoxins containing protein toxin portions can be produced as fusion proteins. The antibodies of the present invention can be used in a corresponding way to obtain such immunotoxins. Illustrative of such immunotoxins are those described by Byers et al.. Seminars Cell. Biol. 2 (1991), 59-70 and by Fanger et al.. Immunol. Today 1 2 ( 1 991 ), 5 1 -54. The above described fusion proteins may further comprise a cleavable linker or cleavage site for proteases. These spacer moieties, in turn, can be either insoluble or soluble (Diener et a! .. Science 231 (1986), 148) and can be selected to enable drug release from the antigen at the target site.

Examples of therapeutic agents, which can be coupled to the antibodies, and antigens of the present invention for immunotherapy are drags, radioisotopes, lectins, and toxins. The drags with which can be conjugated to the antibodies and antigens of the present invention include compounds, which are classically referred to as drags such as mitomycin C, daunorabicin, and vinblastine. In using radioisotopicaily conjugated antibodies or antigens of the invention for, e.g., tumor immunotherapy, certain isotopes may be more preferable than others depending on such factors as leukocyte distribution as well as stability and emission.

Some emitters may be preferable to others. In general, alpha and beta particle emitting radioisotopes are preferred in immunotherapy. Preferred are short range, high energy a emitters such as ²¹²Bi. Examples of radioisotopes, which can be bound to the antibodies, or antigens of the invention for therapeutic purposes are ¹²⁵1, ¹³¹I, ⁹⁰Y, ⁶⁷Cu, ²¹²Bi, ²¹²At, ²¹¹Pb, ⁴⁷Sc, ¹⁰⁹Pd and ¹⁸⁸Re. Other therapeutic agents, which can be coupled to the antibody or antigen of the invention, as well as ex vivo and in vivo therapeutic protocols, are known, or can be easily ascertained, by those of ordinary skill in the art. Preferably, MAGEA3 binding ant ibodies or binding fragments thereof as they are mentioned here include the above-mentioned specific MAGEA3 antibodies which have been characterized inter alia by SEQ ID Nos. 1 to 100 and which may then be further modified as described herein to yield fragments, variants etc. All of these specific individual MAGEA3 binding antibodies or fragments thereof have in common that they have either been directly obtained from patients which suffer from a MAGEA3 expressing tumor and which have been classified as complete or at least partial responders or that they have been derived from antibodies of such patients. They thus arc either monoclonal human patient-derived antibodies or monoclonal chimeric, humanized or human antibodies, binding fragments thereof and their variants, which preserve the essential properties of the monoclonal human patient-derived antibodies. It seems justified to assume that such antibodies and binding fragments thereof will be particularly effective in the treatment of MAGEA3 and/or MAGEA6 expressing tumors or even other cancer types. The effectiveness of such antibodies may result from their capability to induce an immune response against the tumor by e.g.

activating CD4 , CD cytotoxic T cells. Certain antibodies such as 21B4 and 3 1 11 10 and binding fragments, variants etc., which are derived thereof, may be preferred as they seem to have a rather high affinity (31 and 19 pM, respectively). Further, they seem to preferentially recognize MAGEA3 over MAGEAl , MAGEA2, MAGEA4 as well as MAGEAl 0 and to also selectively stain tumor specimen. The present invention further relates to nucleic acid molecules encoding for such antibodies, to nucleic acid molecules encoding for the variable l ight and or heavy chains thereof and to nucleic acid molecules encoding for the CDR 1 , CDR2 and/or CDR.3 of the variable light and/or heavy chains thereof. The present invention further relates to vectors comprising such nucleic acid molecules and/or such vectors.

The present invention also relates to pharmaceutical compositions comprising any of the afore-mentioned MAGEA3 binding antibodies or binding fragments thereof. The present invention further relates to pharmaceutical compositions comprising any of the afore-mentioned M A G E A3 bind i ng antibodies or binding fragments thereof for use in treating hyper-pro! iterative diseases, in particular tumors, which express MAGEA3 and/or MAGEA6.

The present invention further relates to the use of any of the afore-mentioned

MAGEA3binding antibodies or binding fragments thereof in the manufacture of a medicament for treating hyper-proiiferative diseases, in particular tumors, which express MAGE A3 and/or MAGEA6.

The present invention further relates to methods of treating hyper-proiiferative diseases, in particular tumors which express MAGE A3 and. or MAGEA6 by administering to patients any of the afore-mentioned MAGEA3 binding antibodies or binding fragments thereof.

As mentioned, the invention also relates in some embodiment to nucleic acid molecules encoding antibodies and binding fragments thereof, vectors comprising such nucleic acid molecules and host cells comprising such nucleic acid sequences and vectors.

The antibodies and binding fragments thereof may be encoded by a single nucleic acid (e.g., a single nucleic acid comprising nucleotide sequences that encode the light and heavy chain polypeptides of the antibody), or by two or more separate nucleic acids, each of which encode a different part of the antibody or antibody fragment. In this regard, the invention provides one or more nucleic acids that encode any of the forgoing antibodies, or binding fragments (e.g., any of the foregoing light or heavy chain variable regions of .SEQ ID NOs: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94 or SEQ ID os.: 3, 13, 23, 33. 43, 53, 63, 73.83, 93 or any of the CDRs of SEQ I D Nos.: 8,1 8, 28, 38, 48, 58, 68, 78, 88, 98, 9. 19, 29, 39, 49, 59. 69, 79, 89, 99. 1 0, 20, 30, 40. 50, 60, 70, 80. 90 or SEQ I D Nos.: 5, 15, 25, 35, 45. 55, 65, 75, 85. 95, 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 7, 17, 27, 37, 47, 57, 67, 77, 87, 97). The nucleic acid molecules may be DNA, cDNA, RNA and the like.

According to one aspect of the invention, the invention provides a nucleic acid that encodes a heavy chain variable region of an antibody or a portion thereof.

Exemplary nucleic acid sequences are provided in SEQ ID Nos: 1 , 1 1 , 21 , 31 , 41 , 51 , 61 , 71 , 81 , 91. The invention also provides a nucleic acid that encodes a light chain variable region of an antibody or a portion thereof. Exemplary nucleic acid sequences are provided in SEQ ID Nos.: 2, 12, 22, 32, 42, 52, 62, 72, 82, 92.

Also encompassed by the invention are nucleic acids encoding any of the foregoing amino acid sequences of the light or heavy chains that comprise one or more conservative substitutions (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, or 15 conservative substitutions), as discussed with respect to the antibody and antibody fragment of the invention, where the antibody or fragment comprising the

substitution has the same or substantially the same affinity and specificity of epitope binding as one or more of the exemplary antibodies, fragments and sequences disclosed herein. Preferably, the polynucleotide of the invention is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic cells. Expression of said polynucleotide comprises transcription of the polynucleotide into a translatable mRNA. Regulatory elements ensuring expression in eukaryotic ceils, preferably mammalian cells, are well known to those skilied in the art. They usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as transiationai enhancers, and/or naturally associated or heterologous promoter regions. The nucleic acids described herein can be inserted into vectors, e.g., nucleic acid expression vectors and/or targeting vectors. Such vectors can be used in various ways, e.g., for the expression of an antibody or a binding fragment in a cell or transgenic animal. Accordingly, the invention provides a vector comprising any one or more of the nucleic acids of the invention. A "vector^" is any molecule or composition that has the ability to carry a nucleic acid sequence into a suitable host cell where synthesis of the encoded polypeptide can take place. Typically and preferably, a vector is a nucleic acid that has been engineered, using recombinant DNA techniques that are known in the art, to incorporate a desired nucleic acid sequence (e.g., a nucleic acid of the invention). Desirably, the vector is comprised of DNA. However, vectors that are not based on nucleic acids, such as liposomes, are also known in the art and can be used in connection with the invention. The inventive vector can be based on a single type of nucleic acid (e.g., a piasmid) or non-nucleic acid molecule (e.g.. a lipid or a polymer). Alternatively, the vector can be a combinat ion of a nucleic acid and a non-nucleic acid (i.e., a "chimeric^" vector). For example, a piasmid harboring the nucleic acid can be formulated with a lipid or a polymer as a delivery vehicle. Such a vector is referred to herein as a "plasmid-lipid complex" and a "p!asmid-polymer" complex, respectively. The inventive gene transfer vector can be integrated into the host cel l genome or can be present in the host cell in the form of an episome.

Vectors are typically selected to be functional in the host cell in which the vector will be used (the vector is compatible with the host cell machinery such that ampl i fication of the gene and/or expression of the gene can occur). A nucleic acid molecule encoding an antibody or binding fragment thereof may be amplified/expressed in prokaryotic, yeast, insect (baculovirus systems) and/or eukaryotic host cells.

Selection of the host cell w ill depend in part on whether the antibody or fragment is to be post-transitionally modified (e.g., glycosylated and/or phosphorylated ). I f so. yeast, insect, or mammalian host cells are preferable. Expression vectors typically contain one or more of the following components (if they are not already provided by the nucleic acid molecules): a promoter, one or more enhancer sequences, an origin of replication, a transcriptional termination sequence, a complete intron sequence containing a donor and acceptor splice site, a leader sequence for secretion, a ribosome binding site, a polyadenylation sequence, a polyl inker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element.

The invention in some aspects further provides a cell (e.g., an isolated or purified cell) comprising a nucleic acid or vector of the invention. The cell can be any type of cell capable of being transformed with the nucleic acid or vector of the invention so as to produce a polypeptide encoded thereby. The cel l is preferably the cell of a mammal, such as a human, and is more preferably a hybridoma cell, an embryonic stem cell, or a fertilized egg. The embryonic stem cell or fertilized egg may not be a human embryonic stem cell or a human fertil ized egg.

The host cells may be prokaryotic host cells (such as E. coli ) or eukarvotic host cells ( such as a yeast cell, an insect cell, or a vertebrate cell). The host cell, when cultured under appropriate conditions, expresses an antibody or binding fragment which can subsequently be col lected from the culture medium (if the host cell secretes it into the medium ) or directly from the host cell producing it (if it is not secreted).

Selection of an appropriate host cell will depend upon various factors, such as desired expression levels, polypeptide modifications that are desirable or necessary for activity, such as glycosylation or phosphorylation, and ease of folding into a biologically active molecule. A number of suitable host cells are known in the art and many are available from the American Type Culture Collection (ATCC), Manassas, Va. Examples include mammalian cells, such as Chinese hamster ovary cells (CHO) (ATCC No. CCL61) CHO DH FR-cells ( Urlaub et al. Proc. Natl. Acad. Sci. USA 97, 4216-4220 (1980)), human embryonic kidney (HEK) 293 or 293T cells (ATCC No. CR L 1573 ), 3T3 cells (ATCC No. CCL92 ). or PER.C6 cells. The cell comprising the nucleic acid or vector of the invention can be used to produce the antibody or binding fragment thereof, or a portion thereof ( e.g.. a heavy chain sequence, or a light chain sequence encoded by the nucleic acid or vector). After introducing the nucleic acid or vector of the invention into the cell, the cell is cultured under condit ions suitable for expression of the encoded sequence. The antibody, antigen binding fragment, or portion of the antibody then can be isolated from the cell. The TAA binding antibodies or binding fragments thereof as well as the compounds capable of activating the immune system can be formulated in compositions, especially pharmaceutical compositions. Such compositions comprise a

therapeutically or prophylactically effect ive amount of an antibody or binding fragment thereof and/or of compounds capable of activating the immune system in admixture with a suitable carrier, e.g., a pharmaceutically acceptable agent.

Pharmaceutically acceptable agents for use in the present pharmaceutical

compositions include carriers, excipients, diluents, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, tonicity agents.

cosolvents, wetting agents, comple.xing agents, buffering agents, antimicrobials, and surfactants.

The composition can be in liquid form or in a lyophilized or freeze-dried form and may include one or more lyoprotectants. excipients, surfactants, high molecular weight structural additives and. or bulking agents (see for example US Patents

6,685,940, 6,566,329, and 6,372,716).

Compositions can be suitable for parenteral administration. Exemplary compositions are suitable for injection or infusion into an animal by any route available to the skilled worker, such as intraarticular, subcutaneous, intravenous, intramuscular, intraperitoneal, intracerebral (intraparenchymai), intracerebroventricuiar,

intramuscular, intraocular, intraarterial, or intralesional routes. A parenteral formulation typically will be a sterile, pyrogen-free, isotonic aqueous solution, optionally containing pharmaceutically acceptable preservatives.

Examples o non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oieate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringers' dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishes, electrolyte replenishes, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, anti-microbials, antioxidants, chelating agents, inert gases and the like. See generally, Remington's

Pharmaceutical Science, 16th Ed., Mack Eds., 1980, which is incorporated herein by reference.

Pharmaceutical compositions described herein can be formulated for controlled or sustained delivery in a manner that provides local concentration of the product (e.g., bolus, depot effect ) and. or increased stability or half-life in a particular local environment. The compositions can include the formulation of antibodies, binding fragments, nucleic acids, or vectors of the invention with particulate preparations of polymeric compounds such as polyiactic acid, polyglycolic acid, etc., as well as agents such as a biodegradable matrix, injectable microspheres, microcapsular particles, microcapsules, bioerodibie particles beads, liposomes, and implantable delivery devices that provide for the controlled or sustained release of the active agent which then can be delivered as a depot injection.

Both biodegradable and non-biodegradable polymeric matrices can be used to deliver compositions of the present invention, and such polymeric matrices may comprise natural or synthetic polymers. Biodegradable matrices are preferred. The period of time over which release occurs is based on selection of the polymer. Typically, release over a period ranging from between a few hours and three to twelve months is most desirable.

Alternatively or additionally, the compositions can be administered locally via implantat ion into the affected area of a membrane, sponge, or other appropriate material on to which an antibody, binding fragment, nucleic acid, or vector of the invention has been absorbed or encapsulated. Where an implantation device is used. the device can be implanted into any suitable tissue or organ, and delivery of an antibody, binding fragment, nucleic acid, or vector of the invention can be directly through the device via bolus, or via continuous administration, or via catheter using continuous infusion. A pharmaceutical composition comprising a binding antibody or binding fragment thereof and. or compounds capable of activating the immune system can be formulated for inhalation, such as for example, as a dry powder. Inhalation solutions also can be formulated in a liquefied propellant for aerosol delivery. In yet another formulation, solutions may be nebulized.

Certain formulations containing antibodies or binding fragments thereof and/or compounds capable of activating the immune system can be administered orally. Formulations administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of a selective binding agent. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders also can be employed. In some embodiments, the pharmaceutical compositions as mentioned before may comprise a MAGE A3 binding antibody or binding fragments thereof but may not comprise a compound capable of stimulating the immune system. The term

"compound capable of stimulating the immune system" is to be understood as described hereinafter and particularly includes CD40L or anti-CD40 agonistic antibodies such as CP-870,893 or SGN-40 and (iii) anti-CTLA4 antagonistic antibodies such as Tremeiimumab and Ipiiimumab. In some other embodiments, the pharmaceutical compositions as mentioned before may comprise a MAGEA3 binding antibody or binding fragments thereof as the sole pharmaceutically active agent.

Further the MAGEA3 binding antibodies or binding fragments thereof and all types of pharmaceutical compositions as contemplated herein can be administered in methods of treating patients suffering from hyper-proliferative diseases and/or preventing individuals from developing hyper-prol i ferati ve diseases.

The term "hyper-proliferative disease" refers to diseases, which are commonly designated as cancer or tumors.

Unless stated otherwise, the terms "cancer" and "tumor" are used interchangeably herein. These terms in particular relate but are not limited to cancer and tumors selected from the group comprising basal cell carcinoma: bladder cancer; bone cancer such as osteosarcoma; central nervous system tumors such as cerebellar astrocytoma, cerebral astrocytoma malignant gl ioma, era n i o p h a y n g i o m a , ependymoblastoma, ependymoma, meduUoblastoma, medulloepithel ioma., pineal parenchymal tumors of intermediate differentiation, primit ive neuroectodermal tumors, pineoblastoma and spinal cord tumors; Burkitt^'s lymphoma: breast cancer; cervical cancer; chronic myelogenous leukemia; colon cancer; rectal cancer; coiorectai cancer; esophageal cancer; Ewing family of tumors; extrahepatic bile duct cancer; gallbladder cancer; gastrointestinal stromal tumor (GIST); glioma; head and neck cancer; islet cell tumors; Kaposi sarcoma; leukemia; liver cancer; lymphoma; l lodgk in^'s lymphoma: non-Hodgkin^'s lymphoma; T-ce!l lymphoma; mesothelioma; multiple myeloma plasma cell neoplasm; myeloid leukemia; multiple myeloma; nasopharyngeal cancer; neuroblastoma; small cell lung cancer; non-small cell lung cancer; oropharyngeal cancer; osteosarcoma ; ovarian cancer; pancreatic cancer; parathyroid cancer; penile cancer; pharyngeal cancer; phaeochromocytoma; pituitary tumor; prostate cancer; renal ceil cancer; respiratory tract carcinoma; retinoblastoma; skin cancer (melanoma); small intestine cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; testicular cancer; throat cancer; thyroid cancer; transitional cel l cancer of the renal pelvis and ureter; urethral cancer; uterine cancer; vaginal cancer; vulvar cancer and Wilms tumor. Treatment of melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer may be particularly effective when using the MAGEA3 binding antibodies or binding fragments thereof or pharmaceut ical compositions as described herein. As mentioned before, in other embodiments of the first aspect of the invention, the MAGEA3 binding antibodies or binding fragments thereof as described herein are used as a diagnostic tool, e.g. for diagnosing patients suffering from

hyperproiiferative diseases as mentioned herein. It can be preferred to use such antibodies to diagnose the occurrence and or development of e.g. hyperproiiferative diseases, which express MAGEA3 and/or MAGEA6. Such hyperproiiferative diseases may include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer. The MAGE A3 binding antibodies and binding fragments thereof may preferably be used to identify

hyperproiiferative diseases such as the afore-mentioned cancers which are primarily characterized by MAGE A3 and/or MAGEA6 and optionally MAGEA2 overe.xpression over cancers which are characterized in addition or solely by

MAGEA.4, MAGEAl or MAGEAIO overexpression. If a treatment is available that primarily is effective for hypreproiiferative disease such as cancers being

characterized by MAGE A3 and or MAGEA6 and optionally MAGEA2

overexpression, the antibodies of the present invention such as 2 1 B4 and antibodies derived therefrom can be used for stratification of patient populations in clinical trials or as companion diagnostic, i.e. selecting patients for which the treatment will be effective, In one embodiment, the present invention thus relates to a diagnostic composition comprising the MAGEA3 binding antibodies or binding fragments described herein. Such diagnostic compositions may be for use in diagnosing occurrence and/or development of e.g. hyperprol iferative diseases, which express MAGEA3 and/or MAGEA6 and optionally MAGEA2. Such hyperproliferative diseases may include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer.

In another embodiment, the invention relates to MAGE A3 binding antibodies or binding fragments thereof as described herein for use in diagnosing

hyperproliferative diseases. These diseases may express MAGEA3 and/or MAGEA6 and optionally MAGEA2. Such hyperprol i erat i ve diseases may include melanoma. breast cancer, ovarian cancer, non-small ceil lung cancer, multiple myeloma and/or pancreatic cancer. In another embodiment, the present invention relates to the use of MAGEA3 binding antibodies or binding fragments thereof as described herein in the manufacture of a composition and. or medicament for diagnosing hyperproliferative diseases. These diseases may express MAGEA3 and. or MAGEA6 and optionally MAGEA2. Such hyperproliferative diseases may include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer. In yet another embodiment, the present invention relates to a method of diagnosing a hyperproliferative disease in a human or animal being by using MAGEA3 binding antibodies or binding fragments thereof as described herein These diseases may express MAGEA3 and. or MAGEA6 and optionally MAGEA2. Such

hyperprol iterative diseases may include melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer.

Such methods and uses may be conducted outside the human body. To this extent a sample, e.g. a tissue sample may be obtained from an individual, which is suspected to suffer from. e.g. imminent or ongoing cancer development. This sample will then be tested e.g. for MAGEA3 and/or MAGEA6 expression. Typically, this

determination will typically include comparing the expression level of e.g. MAGE A3 and/or MAGEA6 with the respective expression levels of samples, which have been obtained from either healthy individuals or healthy tissue of the same individual.

The inventio thus relates e.g. to a method of diagnosing a hyperproliferative disease in a human or animal indiv idual comprising at least the steps of:

a) Testing a sample of said human or animal individual for expression of at least MAGEA3 using a MAGEA3 binding antibody or binding fragment as described herein;

b) Comparing with, expression of at least MA.GEA3 in a control sample;

c) Determining the occurrence and/or likely development of a hyperproliferative disease by comparing the data obtained in steps a) and b).

Steps a) and b) may preferably be conducted outside the human or animal body. A sample may be tissue, organs, etc. A control sample may be as described before.

Such, methods and uses may, however, also be conducted directly on. the human body. To this extent the antibodies may be labeled with a detectable marker, be ad ministered to an individual, which is suspected to suffer from e.g. imminent or ongoing cancer development and localization of the antibody as well as expression levels of MAGEA3 and. or MAGEA6 will be directly determined in the individual. The invention thus relates e.g. to a method of stratifying a patient population for e.g. cl inical trials for testing treatment of a hyperprol i ferat i ve disease in a human or animal individual comprising at least the steps of:

b) Comparing with expression of at least MAGEA3 in a control sample;

c) Selecting the patient population by comparing the data obtained in steps a) and b). Steps a) and b) may preferably be conducted outside the human or animal body. A sample may be tissue, organs, etc. A control sample may be as described before.

The invention also relates to a method of data acquisition comprising at least the steps of:

a) Administering a MAGEA3 binding antibody or binding fragment thereof as described herein to human or animal individual;

b) Determining the distribution of said MAGEA3 binding antibody or binding fragment thereof in said human or animal individual ; and

c) Determining expression of at least MAGEA3 in said human or animal

individual.

As mentioned above, in a second aspect the present invention relates to a

combination of TAA binding antibodies such as the AG E A3 -b i nd i ng antibodies or binding fragments thereof as described herein and a compound capable of stimulating the immune system. This second aspect of the present invention is inter alia based on the experimental finding that mice with a syngeneic NY-ESO-1 positive colon tumor which were treated with 5-FU display infiltration of CD4 \ CD8 ^' T-cells after administration of NY-ESO- 1 binding antibody 12D7 (having a variable light chain of SEQ ID No. 109 ad and a variable heavy chain of SEQ ID No. 1 10) and that this effect is more pronounced upon additional administration of anti-CD40 agonistic antibodies. As a consequence of these treatments, tumor size is reduced. This NY-ESO-1 binding antibody as well as other speci fic NY-ESO- 1 binding antibodies and fragments thereof are described in detail in EP 1 1 150 527.7.

Without wanting to be held to this hypothesis, it is assumed that administration of TAA binding antibodies such as the CT-antigen NY-Eso- 1 binding antibody 12D7 triggers an immune response, which from a therapeutic perspective (e.g. in terms of tumor destruction) is localized at the site of tumor. It seems that this type of localized immune response can be further augmented and/or prolonged by administration of compounds, which are capable of activating the immune system such as the CD40 agonistic antibodies. It is assumed that the same type of cooperative action can be observed if e.g. MAGEA3 binding antibodies or binding fragments thereof as they are disclosed herein are combined with such compounds, which are capable of activating the immune system.

This combined approach of using very selective tumor targeting agents ( i.e. the TAA binding antibodies such as the MAGEA3 binding antibodies or binding fragments thereof as described herein) with what may be designated as broad band immuno- modulating agents (i.e. compounds capable of stimulating an immune response) and even non-specific cytotoxic agents may provide several advantages that may significantly improve disease therapy. Standard chemotherapy with compounds such as 5-FU, therapies focusing on general immuno-modulators e.g. via to! 1-7 or toll-9 receptor agonists, CD-40 receptor agonists, anti-CTLA-4 antagonistic antibodies and even more targeted therapies involving therapeutic antibodies directed against the EGF-Receptor or HER-2 receptor suffer from various side effects.

Chemotherapy with cytotoxic agents affects dividing cells in general . Immuno- modulators enhance other non-tumor directed immune reactions as well as adverse autoimmune reactions. Antibody addressed EGF-Receptors or HER-2 receptors are of functional relevance not only in tumor tissue but in other di fferentiated normal cells as well e.g. of the heart.

These properties lead to "off- target^" (the target being the tumor) side effects, which can e.g. limit the dosage and thus the effectiveness of these otherwise therapeutically extremely important therapeutic principles.

By the use of TAA binding antibodies and preferably of CT antigen binding antibodies such as the MAGEA3 binding antibodies or binding fragments thereof as described herein which may be monoclonal human patient-derived antibodies as described hereinafter, the therapeutically important effects of systemically active i m m u n e-m od u 1 a t ors may be boosted as these activ ities seem to be more limited to the therapeutic areas of interest, namely the tumor tissue which is pre-selected through the TAA binding antibodies such as MAGEA3 binding antibodies. This assumed p re-selection, of the therapeut ic area of interest, namely the tumor tissue, by TAA binding antibodies such as the MAGEA3 binding antibodies or binding fragments thereof as described herein and the focusing of the broad band activity of i m m u n e - m od u 1 a t i n g agents to these areas of therapeutic interest should limit off- target related adverse events at least to some extent. This should in turn al low e.g. using i m m u n o- m od u I a ting agents such as anti-CD40 agonistic antibodies in higher concentrations than usual and to thus benefit to a greater extent from their therapeutic potential. One may also envisage more effective dosage regimens such as shortened intervals for subsequent administration of the pharmaceutically active agents.

Given that the initial immune response is selectively targeted by the TAA binding antibody such as the MAGE A3 binding antibodies or binding fragments thereof as described herein to tumor tissue only, the additional augmentation seems to also preferentially only effect the tumor tissue only. Such a localized integrated tumor speci fic immune response may be particularly effective if chemotherapy with e.g. 5- FU makes the TAAs such as the MAGEA3 binding antibodies or binding fragments thereof as described herein readily accessible for the TAA binding antibody.

Based on the above observations, it seems justified that the effects observed for the combination of 5-FU, the NY-ESO- 1 binding antibody 12D7 and anti-CD40

agonistic antibodies may also apply for other CT-antigen binding antibodies or TAA binding antibodies in general such as the MAGEA3 binding antibodies or binding fragments thereof as described herein, for other activators of the immune system such as CD40L, anti-OX4() agonistic antibodies, anti-CD 137 agonistic antibodies, anti-CTLA4 antagonistic antibodies, anti PD-1 antagonistic antibodies or anti-CD25 antagonistic antibodies and for other cellular stress inducing therapies such as radiation.

The invention in one embodiment of the second aspect is therefore directed to a pharmaceutical composition comprising at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof such as the MAGEA3 binding

antibodies or binding fragments thereof as described herein and at least one

compound capable of activating the immune system. The combination of such pharmaceutically active agents may also be comprised within a kit of pharmaceutical compositions as it is described hereinafter. It should be understood that the term "kit" indicates that the invention considers the treatment of e.g. hyper-proliferative diseases as mentioned hereinafter by

combinations of pharmaceutically active agents and that these pharmaceutically active agents (e.g. an MAGE A3 binding antibody, an anti-CD40 agonistic antibody and/or an anti-CTLA4 antagonistic antibody) do not need to be combined within a single pharmaceutical dosage form. In fact, it may be advantageous to actually use e.g. an MAGE A3 binding antibody and an anti-CD40 agonistic antibody in the form of separately provided pharmaceutical dosage forms as this will allow accounting e.g. for different pharmacokinetic properties of these antibodies during treatment. The term ^"kit" therefore is also not to be understood as referring to e.g. necessarily simultaneously offering separate pharmaceutical dosage forms, which comprise the pharmaceutical ly active agent even though such type of offering is not excluded. The term "kit^" indicates that the invention focuses on a use of a combination of different pharmaceutically active agents during therapy and that this combination may e.g. be offered as separate single pharmaceutical dosage forms w hich can then be used in e.g. a method or use in accordance with the invention.

The present invention in one embodiment of the second aspect thus also relates to a combination of at least one tumor associated antigen (TAA ) binding antibody or binding fragment thereof such as the MAGEA3 binding antibodies or binding fragments thereof as described herein and at least one compound capable of activating the immune system for use in treating a disease such as a hyper- proliferative disease. The TAA binding antibody or binding fragments thereof and the at least one compound capable of activating the immune system may be selected as described hereinafter. The components of such combination may be used simultaneously or sequentially for treatment of e.g. hyper-proliferative diseases.

The term "Tumor Associated Antigen (TAA)" is used as described above. Example of T A As in general can be taken from Table of EP 1 1 1 50 527.7. The term "compound capable of activating the immune system'^' refers to a pharmaceutically acceptable compound which is capable of prolonging and/or augmenting an initial immune response which has been triggered by a TAA binding antibody or binding fragment thereof such as the MAGEA3 binding antibodies or binding fragments thereof as described herein.

Such compounds can include compounds which are known to stimulate or at least co-stimulate a humoral or cellular immune response even if no a TAA binding antibody or binding fragment thereof such as the MAGEA3 binding antibodies or binding fragments thereof as described herein has been administered prior to.

simultaneous with or after administration of such compounds.

Preferably, the term "compound capable of activating the immune system^" thus refers to a pharmaceutically acceptable compound which stimulates or at least co- stimulates e.g. maturation of Antigen Presenting Cells ( APC) including e.g. dendritic cells, macrophages, neutrophils and eosinophils, T-cell. activation, T-cell proliferation including e.g. CD4 helper T-cell and/or CD cytotoxic T-cell proliferation, expansion of T-cells, maintenance of memory T-cells and/or proliferation of NK. cells. It is to be understood that for the purposes of the present Invention TAA binding antibodies or binding fragments thereof such as CT-antigen binding antibodies or binding fragments thereof and in particular the MAGEA3 binding ant ibodies or binding fragments thereof as described herein are not considered as representatives of "compounds capable of activating the immune system".

The afore-mentioned "compounds capable of activating the immune system" may- exert their activating function on the immune system through different mechanisms.

For example, ^"compounds capable of activating the immune system" may comprise natural components of the immune system which are known to be involved in the sti mul at ion or at least co-stimulation of the aforementioned activities such as e.g. maturation of Antigen Presenting Cel ls (A PC ) including e.g. dendritic cells, macrophages, neutrophils or eosinophils, T-eell activation, T-cell proliferation including e.g. CD4 helper T-eell and. or CDS ¹ cytotoxic T-cell proliferation, expansion of T-cells, maintenance of memory T-cells and/or proliferation of N cel ls. Such natural components of the immune system, which according to the invention are "compounds capable of activating the immune system^" include CD40, CD40 Ligand (CD40L), CD80, CD80 Ligand, C86 and CD86 Ligand, DR5, B7, OX40, CD 137, cytokines such as 11.-2, 11.-6, 11.-8, 11.- 1 0, 11.- 12. TNF-a, MIP- l a, and others. These components form a subgroup of "compounds capable of activating the immune system" and may be designated as "natural stimulants or at least co- stimulants of the immune system". A preferred representative of this subgroup is CD401 "Compounds capable of activating the immune system^" may. however, also comprise compounds which do not constitute natural components of the immune system but which induce and. or increase the activity of the afore-mentioned natural components of the immune system, i.e. have an agonistic effect on "natural stimulants or at least co-stimulants of the immune system^". This subgroup of "compounds capable of activating the immune system" may be designated as

"agonistic activators of natural stimulants or at least co-stimulants of the immune system". Preferred embodiments of this latter subgroup comprise anti-CD40 agonistic antibodies such as CP-870,893, SGN-40, FGK.45.5 or a humanized form thereof, anti-OX40 agonistic antibodies such as 0X86, anti-CD 137 agonistic antibodies such as BMS-6635 13 and others. Information on such factors and antibodies can be taken inter alia from Weiner et a!., (20 10), Nature Reviews, 10, 3 1 7-327, Fonsatti et al., (201 0), Seminars in Oncology, 37(5 ), 5 1 7-523 or

Vonderheide (2007), Molecular Pathways, 13(4), 1 083- 1088. Other "compounds capable of activating the immune system" include compounds which release an inhibitory effect of natural components of the immune system on the aforementioned activities such as e.g. maturation of Antigen Presenting Cells (APC) including e.g. of dendritic cells, macrophages, neutrophils or eosinophils, T- cell activation, T-cell proliferation including e.g. CD4 helper T-cell and. r CD8 cytotoxic T-cell proliferation, expansion of T-ceils, maintenance of memory T-cells and/or proliferation of NK cells. Examples of such natural components of the immune system., which have an inhibitory or at least co-inhibitory effect on the afore-mentioned activities, include e.g. ( LA 4, CD25 PD-1 or sMICA. This further subgroup of "compounds capable of activating the immune system" may be designated as "antagonistic effectors of natural inhibitors or at least co-inhibitors of the immune system". Examples of "antagonistic effectors of natural inhibitors or at least co-inhibitors of the immune system" include anti-CTLA4 antagonistic antibodies such as Tremeiimumab and Ipilimumab, anti-CD25 antagonistic antibodies such as Daclizumab and anti-PDl antagonistic antibodies such as CT-01 1. Information on such factors and antibodies can be taken inter alia from Weber,

(2008), The Oncologist, 13(suppl 4), 16-25 or Fonsatti et al.. (2010), Seminars in Oncology, 37(5), 517-523. In a preferred embodiment of the invention "compounds capable of activating the immune system" are selected from CD40L, anti-CD40 agonistic antibodies including CP-870,893, and SGN-40 and anti-CTLA4 antagonistic antibodies including

Tremei imumab and Ipil imumab. It is to be understood that if antibodies such as anti-CD40 agonistic antibodies including CP-870,893, and SGN-40 or anti-CTLA4 antagonistic antibodies including Tremei imumab and Ipilimumab are used as compounds capable of activating the immune system, they may be used as binding fragments, variants etc. of the

respective antibody. Other "compounds capable of activating the immune system" include compounds, which are known to act on the innate immune system such as activators of Toll-like receptors including Toll-like receptors, 2, 3, 4, 5, 7, 8, and 9. Such compounds include bacterial lipoprotein, LPS, double-stranded RNA. poly I.C (polyinosinic polycytidylic acid), bacterial flagellin rest qui mod. (R848) and CpG-ODN.

As mentioned above, the TAA binding antibodies or binding fragments thereof such as the MAGEA3 binding antibodies or binding fragments thereof as described herein may be combined with compounds capable of activating the immune system in different fashions .

Thus, a TAA binding antibody such as the MAGEA3 binding antibodies described herein may be combined with natural stimulants or at least co-stimulants of the immune system, agonistic activators of natural stimulants or at least co-stimulants of the immune system or with antagonistic effectors of natural inhibitors or at least co- inhibitors of the immune system.

A specific example would be the combination of a MAGEA3binding ant ibody as disclosed herein (such as 2 1 B4 or 1 H 1 0) with anti-CD40 agonistic antibodies such as CP-870,893 or SGN-40. anti-OX40 agonistic antibodies such as 0X86 and/or anti-CD 137 agonistic antibodies such as BMS-663513.

Another specific example would be the combination of a MAGEA3 binding antibody as disclosed herein (such as 2 1 B4 or 3 1 1 1 10) with anti-CTLA4 antagonistic antibodies such as Tremelimumab or Ipilimumab and/or anti-CD25 antagonistic antibodies such as Daclizumab.

However, a TAA binding antibody such as the MAGEA3 binding antibodies or binding fragments thereof as described herei may also be combined with e.g. (i) natural stimulants or at least co-stimulants of the immune system or agonistic activators of natural stimulants or at least co-stimulants of the immune system and (ii) with antagonistic effectors of natural inhibitors or at least co-inhibitors of the immune system. A specific example would be the combination of a MAGE A3 binding antibody or binding fragment thereof as disclosed herein (such as 24 B 1 or 3 1 H 10) with anti- CD40 agonistic antibodies such as CP-870,893 or SGN-40 and with anti-CTLA4 antagonistic antibodies such as Tremelimumab or Ipilimumab. Other examples may further include 0X86, BMS-663513, CT-01 1 and/or

Daclizumab.

Further compounds, which are known to act on the innate immune system such as activators of Toll-like receptors 1 , 2, 3, 4, 5, 7, 8, and 9 may be included.

A preferred embodiment comprises a combination of a MAGE A3 binding antibody as disclosed herein (such as 23 B l or 3 1 H 10) w ith anti-CD40 agonistic antibodies such as CP-870,893 or SGN-40 as the sole pharmaceutically active agents. Another preferred embodiment comprises a combination of a MAGE A3 binding antibody as disclosed herein (such as 24 B l or 301 1 10) with anti-CTLA4 antagonistic antibodies such as Tremelimumab or Ipilimumab as the sole pharmaceutical ly active agents. Yet another preferred embodiment comprises a combination of a MAGEA3binding antibody as disclosed herein (such as 24 B 1 or 3 1 H 10) with anti-CD40 agonistic antibodies such as CP-870,893 or SGN-40 and w ith anti-CTLA4 antagonistic antibodies such as Tremelimumab or Ipil imumab as the sole pharmaceutically active agents. It has been mentioned above that the different pharmaceutically active principles such as the MAGEA3 binding antibody or binding fragment thereof, natural stimulants or at least co-stimulants of the immune system, agonistic activators of natural stimulants or at least co-stimulants of the immune system or antagonistic effectors of natural inhibitors or at least co-inhibitors of the immune system may be combined within multi-specific antibodies such as bi-spccific antibodies or binding fragments thereof. This will be illustrated for the specific example of a MAGEA3 binding antibody and an anti-CD40 agonistic or an anti-CTLA4 antagonistic

antibody or binding fragment thereof. However, it will be understood that this principle can be extended to other compounds capable of activating the immune system as well.

Thus, a portion of a MAGE A3 binding antibody or binding fragment thereof and (i) a port ion of an anti-CD40 agonistic ant ibody or binding fragment thereof or (ii) a portion of an anti-CTLA4 antagonistic ant ibody or binding fragment thereof may be combined in a bi-specific antibody.

Such bispecific antibodies or fragments can be of several configurations. For example, bispecific antibodies may resemble single antibodies (or antibody fragments) but have two different antigen binding sites (variable regions). Bispecific antibodies can be produced by chemical techniques (Kranz et al. (1981), Proc. Natl. Acad. Sci. USA, 78: 5807) or by recombinant DNA techniques. Bispecific antibodies can have binding specificities for at least two different epitopes, at least one of which is an epitope of the tumor-associated antigen for which the antibody has been identified. The antibodies and binding fragments can also be heteroantibodies.

Heteroantibodies are two or more antibodies, or antibody binding fragments ( Fab) linked together, each antibody or fragment having a different specificity.

The use of such bispecific antibodies can have the advantage that the augmentation and/or prolongation of the initial localized immune response which is assumed to be triggered by the TAA binding antibody is confined to the tumor as precisely as possible.

This concept can, of course be extended to tri-specific ant ibodies which would comprise e.g. a portion of a MAGEA3 binding antibody or binding fragment thereof, a portion of an anti-CD40 agonistic antibody or binding fragment thereof and a portion of an anti-CTLA4 antagonistic antibody or binding fragment thereof.

As has been set out before, the afore-mentioned combinations may be provided in the form of a single pharmaceutical composition which would be the case e.g. for a bispecific antibody or they may be provided as a kit of pharmaceutical compositions.

Where a kit is contemplated, it may comprise the pharmaceutically active agents in separate pharmaceutical compositions in different combinations. This will again be illustrated for the specific example of a cytotoxic agent, a MAGEA3 binding antibody, an anti-CD40 agonistic antibody and an anti-CTLA4 antagonistic antibody. However, it will be understood that this principle can be adapted accordingly to other combinations. In the aforementioned example, the kit may consist of two pharmaceutical compositions, the first pharmaceutical composition comprising the cytotoxic agent and the second pharmaceutical composition comprising a MAGEA3 binding antibody and an anti-CD40 agonistic antibody. This kit would allow to first treating a patient with chemotherapy which is assumed to make (in this case) the MAGEA3 and. or MAGEA6 antigen more readily accessible to the MAGEA3 binding antibody. However, the subsequent administration of the second pharmaceutical composition then ensures simultaneous delivery of both the MAGE A3 binding antibody and the anti-CD40 agonistic antibody. This will allow the anti-CD40 agonistic antibody to display its activity as soon as the MAGEA3 binding antibody has triggered a localized immune response. In another example, the kit may consist of three pharmaceutical compositions, the first pharmaceutical composition comprising the cytotoxic agent, the second pharmaceutical composition comprising a MAGEA3 binding antibody and the third pharmaceutical composition comprising an anti-CTLA4 antagonistic antibody. This kit would allow to first treating a patient with chemotherapy which is assumed to make (in this case) the MAGEA3 antigen more readily accessible to the MAGEA3 binding antibody. The second and third pharmaceutical compositions could then be administered separately from each other to first trigger a localized immune response by the TAA binding antibody and to allow sufficient time for development of such an immune response before the anti-CTLA4 antagonistic antibody can fully exert its function. However, the anti-CTLA4 antibodies may also help to de-repress already existing MAGE A3 specific T-cells. These ceils could be further activated by the subsequent administration of MAGE A3 speci ic antibodies, which would further strengthen the MAGEA3 binding antibody mediated antigen presentation. For such case the third pharmaceutical composition may be administered before or at least concomitantly with the second pharmaceutical composition.

Such kits could thus be used to e.g. account for the different pharmacokinetic properties of the e.g. respective antibodies by a fine-tuned timely administration.

It has been mentioned above that the efficacy of the aforementioned combinations may be enhanced if the patients receiving such combinations are subjected to a cytotoxic treatment.

The term "cytoto ic treatment^" includes chemotherapy, radiation therapy, surgery, hyperthermia and the like. Chemotherapy may include administration of cytotoxic agents such as taxanes including docetaxel and paclitaxel, anthracyciines, cisplatin, carbopiatin, 5-fluoro-uracil, gemcitabine, capecitabin, navelbine or zoledronate. Where chemotherapy and particularly the aforementioned cytotoxic agents are used as cytotoxic treatment, these agents may be included in the pharmaceutical compositions and kits as contemplated above. Prefe ably, 5-FU may be included. The combinations of pharmaceutically active agents, which may take the form of pharmaceutical compositions or kits as contemplated herein can be used as medicaments for use in treating patients suffering from hyper-prol i ferati ve diseases.

The combinations of pharmaceutical ly active agents, wh ich may take the form of pharmaceutical compositions or kits as contemplated herein can be also used in the manufacture of medicaments for treating patients suffering from hyper-prol i ferati ve diseases.

Further the combinations of pharmaceutically active agents, w hich may take the form of pharmaceutical compositions or kits as contemplated herein can be admin istered in methods of treating patients suffering from hyper-prol iferative diseases.

The term "hyper-prol i ferati ve disease" is used as mentioned above. The use of MAGEA3 binding antibodies or binding fragments thereof as described herein together w ith compounds capable of stimulating the immune system may be particularly useful for treatment of melanoma, breast cancer, ovarian cancer, non- small cel l lung cancer, multiple myeloma and. or pancreatic cancer may be particularly effective. The efficacy and. or selectivity of pharmaceutical compositions or kits in accordance w ith the invention towards certain cancers may be increased if different TAA binding antibodies or binding fragments w hich bind to e.g. different CT antigens are present are combined. Thus, the above-mentioned pharmaceutical compositions or kits may comprise e.g. combinations of MAGE A3 and NY-ESO- 1 binding antibodies or binding fragments thereof w ith e.g. anti CD40 agonistic or binding fragments thereof and/or anti-CTLA4 antagonistic antibodies or binding fragments thereof. Other combinations can be taken from. EP 1 1 150 527.7.

The combination of MAGE A3 binding antibodies or binding fragments thereof with compounds capable of stimulating the immune system can be applied in the form of pharmaceutical compositions as described with respect to pharmaceutically acceptable excipients, routes of administrat ion etc.

I f the MAGEA3 binding antibodies or binding fragments thereof are used in combination with compounds capable of stimulating the immune system, such antibodies may take the above-described forms (single chain antibodies etc. ) or may be modified with labels as described above.

The combination of MAGEA3 binding antibodies or binding fragments thereof w ith compounds capable of stimulating the immune system may also be used for methods of treatment as described above and pharmaceutical compositions or kits comprising a combination of MAG E A3 binding antibodies or binding fragments thereof w ith compounds capable of stimulating the immune system may be appl ied for the uses described above.

The invention is now described with respect to some examples which are however not be construed as l imiting.

Experiment 1 : Isolation of MAGEA3 antibodies

Patient Material

Serum and peripheral blood lymphocytes for the isolation of memory B cells was collected from patients in accordance w ith the informed consent that was approved by the local Ethical committee and signed by the patient. Antibodies 54B4. 43 B I O, 94G1 1 , 9A5, 20C 10, and 4D6 were derived from a patient with a metastatic mammary carcinoma showing prolonged survival as compared to peer group after resection of primary tumor, radio-and chemo- and biological (Trastuziimab) therapy. Antibodies 21B4, 3 1 1 1 10, 26C9 and 2G4 were derived from a patient with metastatic rectal carcinoma who was treated w ith chemo- and biological (Cetu imab) therapy. Both patients had sponteanous antibody titers against MAGEA3 in their serum.. Memory B cell culture

Memory B cells were isolated from human peripheral blood monocytic cells with a two step selection procedure using MACS beads against the pan-B cell marker CD22 ( Miltenyi, Bergisch Gladbach, Germany) followed by staining with phycoerythrin- conjugated mAbs anti human IgD and A PC-conjugated antibodies anti human IgM, CD3, CDS, CDS 6 (Becton Dickinson, Basel. Switzerland). Alternatively, a one step protocol was appl ied using phycoerythrin-conjugated mAb anti-human IgD, A PC- con jugated mAbs anti-human IgM, CD3, CD56, CD8 and FiTC-conjugated mAb anti human CD22 (Becton Dickinson, Basel, Switzerland). Cell sorting was carried out using a MoFlo XDP cell sorter (Beekman Coulter). CD22-positive- and IgM-,

IgD-negative B cells were then incubated with EBV containing supernatant obtained from B95-8 ceils (in B ceil medium containing RPMI 1640 supplemented with 10% fetal calf serum). Cells were seeded in at 10 cells per well in IMDM medium supplemented with CpG 2006 on 30.000 irradiated feeder PBL prepared from voluntary donors.

After I 1 - 14 days of culture the conditioned medium of memory B cell culture was screened for the presence of MAGEA3-specific antibodies by ELISA. M AGE A3 ELISA

His-tagged MAGEA3 expressed in bacteria was column purified and used to coat 96 well microp!atcs ( Costar, USA). Plates were washed with PBS-T and blocked 1 h at room temperature w ith PBS containing 2% BSA (Sigma, Buchs, Switzerland).

Patient sera, B cell conditioned medium, or recombinant antibody preparations were incubated for 2h at room temperature. Binding of human IgG to MAGEA3 was determined using a horseradish peroxidase conjugated goat anti human Fc-gamma- spccifie antibody (Jackson ImmunoResearch, Europe Ltd., Cambridgeshire, UK) followed by measurement of the HRP activity using a TMB substrate sol ution (TMB, Sigma, Buchs, Switzerland).

Molecular cloning of human antibodies specific to MAGEA3 Single cells obtained from MAGEA3 -reactive memory B cell cultures were deposited into a 96 w ell PGR plate, containing first strand buffer ( Invitrogen.

LuBioScience, Switzerland). cDNA was prepared using Random hexamer primer ( Invitrogen, LuBioScience, Switzerland ). PGR amplification of immunoglobulin heavy and light chain variable regions was performed according to standard protocols ( Wardemann et al. Science 301 , 2003, 1374 1377). Immunoglobul in heavy and light chain variable regions were amplified using a nested PGR approach. 1 st round PGR was performed with primers specific for the IgG constant region and primer mixes specific for all signal peptides of heavy and light chain Ig variable region families (Wardemann et al. Science 30 1 , 2003. 1374 1377 ). Subsequently, nested PGR was performed using primer mixes specific for the immunoglobul in J- regions and the 5 ' region of framework 1 of heavy and light chain Ig variable region families. Sequence analysis w as carried out to identify the individual antibody clones present in the selected B cell culture. Subsequently, the Ig-variable heavy- and light regions of each antibody clone were cloned into expression vectors providing the constant regions of human IgG 1 . human Ig- appa or human Ig-Lambda. Upon co- transfection. of the Ig-heavy- and light expression vectors into HEK 293 cells the antibody clones were produced. Identification of the antibody clone presumably responsible for the MAGEA3 -reactivity of the parental B cell culture was performed upon re-screening of the recombinant antibody clones in MAGE A3- and control El. IS A. This approach led to identification of 21B4, 31H10, 54B4, 43 B I O. 94G1 1 , 9A5, 26C9, 20C 10, 2G4 and 4D6.

In order to identify and to correct primer encoded sequence mismatches in the Ig- variable region a further PGR amplification using a semi-nested protocol was performed with 2 primer pairs specific for a conserved region of the Ig-heavy- and light chain constant regions as 3 ' - primers and primer mixes specific for the Ig-signal peptides as 5 '-primers. PGR. products were cloned into TOPO™ vector (Invitrogen, LuBioScience, Lucerne, Switzerland). Sequence determination of the complete Ig- variable region was carried out and the information was used to design specific primers for the cloning of the authentic human antibody sequence into antibody expression vectors. This approach was applied to antibodies 21B4, 31H10, 54B4, 94G1 1 1 , 9A5, 26C9, 20C 10 and 2G4 resulting in the identification of the complete antibody sequence of the Ig-variable region as it occurred in the patient. This sequence was used for recombinant production of these antibodies which were then used in the subsequent characterization steps.

Antibody production and purification

Transient gene expression of human ant ibodies was achieved upon transfection of antibody expression vectors into 293-T human embryonic kidney cells or Chinese Hamster Ovary cel ls (CI 10 using the Polyethylenimine Transfection method (PEI, Poly science Warrington, USA). After transfection cells were cultured in serum free medium (OPTI-MEM I supplemented with GiutaMAX-I Gibco). Supematants were collected after 3-6 days of culture and IgG was purified using protein A columns (GE HealthCare, Sweden) on a fast protein l iquid chromatography device (FPLC) (GE HealthCare, Sweden).

Experiment 2: Epitope mapping of antibodies

Epitope Mapping ELISA

20mer peptides spanning the entire MAGEA3 protein with. 10 aa overlaps shared by each adjacent peptide (Peptides&E!ephants, Nuthetal. Germany) were used to coat Maxisorp ELISA plates (Nunc. Rochester, NY ). As control a 20mer peptide representing amino acids 40-21 from, the NY-ESO-1 protein was used (rev). The amino acids of MAGEA.3 represented by the 20m.er peptides are indicated in the table below. The numbering of amino acids of MAGEA3 is based on SEQ ID No.: 101.

Human recombinant antibody was used at a concentration of 1 fig ml with the exception of antibody 9A5 which was used at 4 mg ml. Bound human antibody was detected using horseradish perox idase-con j ugated goat an ti -human IgG Fc-gamma specific antibodies (Jackson ImmunoResearch, Europe Ltd., Cambridgeshire, UK).

The results are depicted in Fig. 1 Experiment 3: !mmunoprecipitation of MAGE A3

Purified recombinant MAGE A3 protein and lysate prepared from SK-Mel-37 cells known to endogenously express MAGE A3, were incubated w ith human MAGEA3- specific antibody follow ed by incubation with Protein G beads (New England Biolabs, Bioconcept, Allschwil, Switzerland). Bound protein was analyzed by Western Blot after Gradient SDS Po!yacrylamidc Gel Electrophoresis ( NuPage 4- 12% Bis-Tris Gel, Invitrogen, LuBioScience. Lucerne, Switzerland). As detection antibody the mouse monoclonal antibody M3H67 was used (provided by LICR, New York, USA ).

The results are depicted in Fig. 2. Experiment 4: Differential binding to members of the MAGEA-family of proteins

Binding of antibodies 21B4, 3 1 H 10, 54B4, 94G 1 1 , 9A5, 2G4 to selected members of the MAGEA-family of proteins was tested in series of assays that display the members as recombinant proteins either expressed in bacteria or eukaryotic cells. The results are depicted in Fig. 3.

4 A: Differential binding to MAGEA3 and MAGEA4 in Western Blot.

Recombinant MAGEA3- and recombinant MAGEA4-protein were displayed on membranes after separation in SDS-PAGE and Western blotting. Membranes were incubated with human antibodies 21B4, 54B4, 94G 1 1 , 9A5. 3 1 H 10, 43 B I O, 2G4 or 20C10. Binding of human antibodies to proteins on the membrane was evaluated. The results are depicted in Fig. 3 A). 4B: Differential binding to MAGE A3, MAGEA1 , MAGEA4 and MAGEA10 in ELISA.

Recombinantly expressed MAGEA3, MAGEA1 , MAGEA4, MAGEA10 were coated on ELISA plates and binding of MAGEA3 antibodies 21B4, 94G1 1 , 2G4, 9A5 and 54B4 to these proteins was tested. The results are depicted in Fig. 3B).

Experiment 4C: Binding to MAGEA6.

HEK293T ceils expressing MAGEA6 upon transient transfection with a MAGEA6 expressing pl sm id were used to demonstrate presence or absence of binding to MAGEA3 by human-derived antibodies 21B4, 3 1 I I 1 0. 94G1 1 and 54B4.

HEK293T cells transiently transfected with MAGEA3 or MAGE A6 were fixed and permeabilized and incubated with human-derived antibodies. Binding of human - derived antibodies to the cells was detected by flow cytometry using PE-labeled anti- human antibodies. Data are displayed as histogram plots. Filled histograms show binding of 21B4, 31H10, 94G1 1 and 54B4 to transiently transfected HEK 293 cells. Only a proportion of the cells was transfected resulting in a population expressing the transgene and in a population not expressing the transgene. Controls were performed using antibody rituximab specific for human CD20 (displayed in histograms as black dotted line, open histograms), and secondary antibody only (displayed in histograms as solid grey lines, open histograms). The results are depicted in Fig. 3C).

The results are summarized in the below table and depicted in Fig 3. 21B4 31H10 54B4 43B10 94G11 9A5 26C9 20C10 2G4 4D6

MAGE-A3 + + + + + + + + + +

MAGE-A6 + + + Not + Not Not Not Not Not done done done done done done

Not Not Not ot Not

MAGE-A1 - _

done done done - N

done done - Not done

Not Not

MAGE-A4 - - - done - - Not

done done - Not done t Not Not

MAGE-A10 - No

done done done - - Not Not

done done - Not done

(+) = binding; (-) =no binding

Experiment 5: EC50 determination of MAGEA3 antibodies

The EC50, the concentration at which hal f-ma imal binding of the antibody to its antigen is observed was determined in MAGEA3 ELISA using serial dilutions of the human monoclonal antibodies 21B4, 54B4, 94G1 1 , 9A5, 31H10, 43 B I O, 2G4, 20C 10, 26C9 and 4D6. EC50 values were determined mathematically by derivation of the best-fit l ine using GraphPad software.

The results are depicted in Fig. 4 Experiment 6: Histology

Formalin fixed and paraffin embedded human tissue (normal testis, prostate, lymph node, heart, colon and squamous cell carcinoma of the lung) was de -waxed and heat treated in high pi 1 Tris buffer to allow for antigen retrieval. Human primary antibody 21B4 was used as FITC-conjugate. Binding of human antibody to tissue was detected using a rabbit polyclonal anti-FITC antibody (Dako, Baar, Switzerland) followed by incubation with polymeric anti-rabbit HRP ( Ultr View HRP-K.it, Ventana, Tucson, USA ). Complexes of primary antibody, secondary antibody and polymeric anti- rabbit HRP were visualized using DAB followed by a counter stain with hematoxilin.

The results are depicted in Fig. 5

Experiment 7: T ceil stimulation Monocyte-derived DC Monocytes are isolated from PBMC obtained from a voluntary donor using anti CD14 antibodies coupled to magnetic particles (MACS, Miltenyi Biosciences,

Bergisch G!adbach. Germany). Monocytes are cultured at a cel l density of 2 x

ΙΟΕχρό /ml in DC medium (CellGro DC media, CellGenix Freiburg, Germany) supplemented with GM-CSF and i L-4 (Peprotech, London, U ). On day 5

Monocyte-derived DC are harvested and incubated with immune complexes in a 96- well flat-bottom plate. Maturation is induced by the addition of TNF-alpha and sCD40L.

Immune complex formation

Recombinant MAGEA3 protein is incubated with the various human monoclonal antibodies at an equimolar ratio in CellGro medium.

T cell stimulation assay

Matured Monocy te-deri ved DC co-incubated or not with immune complexes and MAGEA3 specific CDS T cells corresponding are incubated in microtiier plates with a 1 : 1 cel lular ratio in RPMI supplemented with human serum and Brefeldin A. Production of intracellular IFN-gamma is then monitored after permeabil ising and fixing the cells using intra cellular staining with fluorescently labeled antibodies anti- IFN-gamma. Experiment 8: Antibody-mediated anti-tumor effects in vivo

Mice are inoculated with syngeneic tumor cells expressing MAGEA3 and cytotoxic therapy is applied once the tumors are palpable. Subsequently, M AG E A -spec i fic antibody is administered. Effects of treatment on tumor growth are measured by monitoring tumor area over time using a caliper.

Induction and/or enhancement of immune effector cell activity against the tumor will be measured by analysis of tumor infiltrating lymphocytes, ex vivo CTL-assays, ex vivo cytokine secretion, in vivo CTL-assays or by monitoring shifts in immune effector cell repertoire subsequent to administration of MAGEA3-specific antibody in comparison to controls.

Experiment 9: Comparison human-derived monoclonal antibody 21B4 vs. murine mAb M3H67

The murine monoclonal antibody M3H67 is commonly considered as the standard detection antibody for MAGEA3 in ELISA, Western blot and Immunohistochemisty (IHC). 21B4 was therefor expressed in recombinant fashion and compared to the murine monoclonal antibody M3H67.

Comparison of21B4 to M3H67 in MAGEA-family ELISA

MAGEA-ELISA using plates coated with recombinant MAGEA 1 , MAG EA3, MAGEA4 and MAGEAIO serial dilutions of the human monoclonal antibodies 21B4 and the murine antibody M3H67 were carried out. 21B4 did not exhibit any cross reactivity with other MAGE A antigens tested. However, it was noted that the control antibody, M3H67, showed binding to all MAGE antigens tested (see Fig. 6).

Comparison of 21B4 to M3H67 in MAGE A3 -protein in Western Blot

The ability of 21B4 and M3H67 to detect recombinant purified MAGEA3 protein or endogenous MAGEA3 from cell ly sates was tested in Western blot. 21B4 detected recombinant MAGEA3 and MAGEA3 in SK.-MEL-37 lysate. M3H67 detected MAGEA3 but also MAGEA4 as recombinant proteins. With SK-MEL-37 cell lysate M3H67 detected a protein with a size distinct from MAGE A3 (see Fig. 7)

Human-derived antibody 2 1 B4 displays a higher speci ficity to MAGEA3 and a higher sensitivity as compared to mAb M3H67 in two distinct biochemical assays. Comparison of human-derived monoclonal antibody 21B4 to murine monoclonal antibody M3H67 in immunohistochemistry

IHC of normal tissue The specificity of human-derived antibody 21B4 and M3H67 was also compared in immunohistochemistry (IHC) of formalin-fixed and paraffin-embedded human tissue. For use in IHC human recombinant monoclonal antibody 21B4 was converted to a human-mouse chimeric antibody featuring the human immunoglobuli variable regions of 2 1 B4 combined with a murine Fc-region (see Fig. 8). Thus, 2 1 B4

corresponds to M3H67 with respect to its ability to be compatible with automated IHC staining systems (secondary antibodies, linker systems etc.).

As a positive control, normal human testis tissue was stained with either 2 1 B4 or M3H67. As negative control. Kidney and Pancreas tissues were chosen due to their supposed lack of MAGEA3 expression. As shown in Fig. 9, 21B4 stains distinct (arrow) in the testis whereas M3H67 stains all spermatogonia and some interstitial tissue. The broad range of reactivity of

M3H67 as demonstrated in the biochemical assays suggests that other MAGEA- family members expressed in testis tissue were recognized. Both antibodies did not show any staining in the negative control tissue.

IHC of Head and Neck cancers: Distinct specificity of 21B4 Tissue derived from, three different patients with, head and neck cancer was analyzed by IHC with 21 B4 and M3H67 (see Fig. 10). Whereas in case 1 no major difference was observable, case 2 only stained positive with 21B4 and case 3 only with M3H67. Whereas cases 1 and 3 ca be explained a) by the by lower affinity of M3H67 to MAGEA3, in b) the absence of any staining with 21B4rc and the prominent staining with M3H67 can be explained by the broad reactivity of M3H67 to MAGEA-family members other that MAGE A3 (or MAGEA6). In marked contrast. Case 2 where 21B4rc stains cancerous tissue lesions where M3H67 does not suggests either a much higher sensitivity of 2 1 B4rc to MAGEA3 or the lack of specificity of M3H67 to some forms of tissue MAGE A3.

In summary, 21B4 displays a well distinguishable staining pattern as compared to M3H67. Moreover, this data supports the notion of M3H67 not being truly specific to MAGEA3.This has implications for the use of either antibody in diagnostic procedures aiming at defining patient populations who are eligible for e.g.

MAG EA3-specific immunotherapy (companion diagnostic). Here, usage of 2 1 B4 in IHC could be used to eliminate false positives (case 3) and false negatives (case 2) of the current assay with M3H67. Thus, 2 1 B4 would be better suited to identify those patients who bear a M A G E A3 -posi t i ve cancer and are thus l ikely to benefit from such, a therapy. Some embodiments of the invention relate to:

1. Isolated monoclonal MAGEA3 -binding antibody or binding fragment thereof.

2. Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to embodiment 1., which binds preferentially to MAGEA3.

3. Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to embodiment 1 . or 2., which binds to MAGE A3 but not to

MAGEA4.

4. Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to any of embodiments 1., 2. or 3., which binds to MAGE A3 but not to MAGEA4, MAGEA1 and/or MAGEA10.

5. Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to any of embodiments 1., 2., 3., or 4., which binds to MAGEA3 but not to MAGEA2.

6. Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to any of embodiments 1., 2., 3., 4., or 5., which binds to MAGE A3 but not to MAGEA6.

7. Isolated monoclonal MAGE A3 -binding derived antibody or binding fragment thereof according to any of embodiments 1., 2. , 3. , 4. , 5. or 6., which binds to MAGEA3 with a KD of about 300 pM or less.

8. Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to embodiment 7., which binds to MAGEA3 with a KD of about 200 pM or less. Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to embodiment 8., which binds to MAGE A3 with a KD of about 1 00 pM or less. Isolated monoclonal M AG E A 3 -b i tid i ng antibody or binding fragment thereof according to embodiment 9., which binds to MAGE A3 with a K_D of about 50 pM or less.

Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to any of embodiments 1 ., 2., 3.. 4., 5., 6., 7., 8., 9.. or 1 0., which binds to an epitope comprising SEQ ID No. 1 02.

Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to any of embodiments 1., 2., 3., 4., 5., 6., 7., 8., 9., or 10., which binds to an epitope comprising SEQ ID No. 103.

Isolated monoclonal M AG E A3 -b i nd i ng antibody or binding fragment thereof according to any of embodiments 1., 2., 3., 4., 5., 6., 7., 8., 9., or 10., which binds to an epitope comprising SEQ I D No. 104.

Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to any of embodiments 1 ., 2., 3., 4., 5., 6., 7., 8., 9., 1 0.. 1 1 ., 1 2.. or 1 3.. which comprises a light chain variable region and/or a heavy chain variable region, w herein

the light chain variable region comprises at least a CDR l selected from SEQ I D Nos.: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 9. 1 9. 1 9. 29, 39, 49, 59, 69, 79, 89, 99 or sequences at least 80% identical thereto, and or a CDR3 selected from SEQ ID Nos.: 10, 20, 30, 40, 50, 60, 70, 80, 90, 1 00 or sequences at least 80% identical thereto; and/or wherein

the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 5, 1 , 25, 35, 45, 55, 65, 75, 85, 95 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6, 1 6, 26, 36, 46, 56, 66, 76, 86, 96 or sequences at least 80% identical thereto, and. or a CDR3 selected from SEQ ID Nos.: 7, 17, 27, 37, 47, 57, 67, 77, 87,97 or sequences at least 80% identical thereto. 1 5. Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to embodiment 14., which comprises a light chain variable region and/or a heavy chain variable region, wherein

a. the light chain variable region comprises at least a CDRl selected from SEQ

ID Nos.: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos. : 9, 19. 19, 29. 39, 49.

59, 69, 79, 89, 99 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 10, 20, 30, 40. 50, 60, 70, 80, 90, 100 or sequences at least 80%> identical thereto; and. or wherein

b. the heavy chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 5, 15, 25, 35, 45, 55, 65, 75, 85, 95 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6, 16, 26. 36, 46, 56, 66, 76, 86, 96 or sequences at least 80%> identical thereto, and a CDR3 selected from SEQ ID Nos.: 7, 17, 27. 37, 47, 57, 67, 77, 87,97 or sequences at least 80% identical thereto.

16. Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to any of embodiments 1 ., 2.. 3.. 4., 5.. 6.. 7., 8., 9., 10., 1 1., 12., or 13., which comprises a light chain variable region comprising SEQ ID Nos.: 4, 14, 24, 34, 44, 54. 64, 74, 84, 94 or sequences at least 80% identical thereto and/or a heavy chain variable region comprising SEQ ID Nos.: 3, 13, 23, 33,

43, 53, 63, 73, 83, 93 or sequences at least 80% identical thereto.

Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to embodiment 16., which comprises a light chain variable region comprising SEQ 11 ) Nos.: 4. 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93 or sequences at least 80% identical thereto.

Isolated monoclonal M A G E A 3 - b i n d i n g antibody or binding fragment thereof which binds to MAGEA3 and which comprises a light chain variable region and. or a heavy chain variable region, w herein

a. the light chain variable region comprises at least a CDR1 selected from SEQ

I D Nos.: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 9, 19. 19, 29, 39. 49, 59. 69. 79, 89, 99 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ ID Nos.: 10, 20, 30, 40. 50. 60, 70, 80, 90, 100 or sequences at least 80% identical thereto; and. or wherein

b. the heavy chain variable region comprises at least a CDR.1 selected from SEQ

I D Nos.: 5, 15, 25. 35, 45. 55, 65, 75, 85, 95 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6. 16. 26. 36, 46, 56, 66. 76, 86, 96 or sequences at least 80% identical thereto, and or a CDR3 selected from SEQ ID Nos.: 7, 17, 27, 37, 47, 57. 67. 77. 87,97 or sequences at least 80% identical thereto.

Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to embodiment 1 8., which comprises a light chain variable region and. or a heavy chain variable region, wherein the light chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos. : 9, 19, 19, 29, 39, 49, 59, 69, 79, 89, 99 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 1 0, 20, 30, 40, 50, 60, 70, 80, 90, 100 or sequences at least 80%> identical thereto; and. or wherein

the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 5, 15, 25, 35, 45, 55, 65, 75, 85, 95 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96 or sequences at least 80%> identical thereto, and a CDR3 selected from SEQ ID Nos. : 7, 17, 27, 37, 47, 57, 67, 77, 87, 97 or

sequences at least 80% identical thereto.

Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to embodiment 19., which comprises a light chain variable region and. or a heavy chain variable region, wherein

the light chain variable region comprises at least a CDRl selected from SEQ

ID Nos.: 8, 18 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ ID Nos.: 9, 19 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 10, 20 or sequences at least 80% identical thereto; and/or wherein

the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 5, 1 5 or sequences at least 80%> identical thereto, a CDR2 selected from SEQ I D Nos.: 6, 16 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ I D Nos.: 7, 1 7 or sequences at least 80%> identical thereto.

Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof which binds to MAGEA3 and which comprises a light chain variable region comprising SEQ ID Nos.: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and/or a heavy chain variable region comprising SEQ ID Nos.: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93 or sequences at least 80% identical thereto. 22. Isolated monoclonal MAGE A3 -binding antibody or binding fragment

according to embodiment 21. which comprises a light chain variable region comprising SEQ I D Nos.: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93 or sequences at least 80% identical thereto.

Isolated monoclonal MAGEA3 -binding antibody or binding fragment according to embodiment 22. which comprises a light chain variable region comprising SEQ I D Nos.: 4. 14 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ ID Nos.: 3, 13 or sequences at least 80% identical thereto.

24. Nucleic acid molecule comprising a nucleic acid sequence coding for a

variable heavy chain of SEQ ID No.: 3, 1 3, 23, 33. 43. 53, 63, 73, 83, 93 or a sequence 80%> identical thereto.

25. Nucleic acid molecule comprising a nucleic acid sequence coding for a

variable light chain of SEQ I D No.: 4, 14, 24, 34, 44, 54, 64, 74. 84, 94 or a sequence 80% identical thereto.

26. Nucleic acid molecule comprising a nucleic acid sequence coding for a

variable heavy chain region CRD of SEQ ID Nos. : 5, 15, 25, 35. 45. 55, 65. 75, 85. 95, 6, 1 6, 26, 36, 46, 56, 66, 76, 86, 96, 7, 17, 27, 37, 47, 57. 67. 77. 87, 97 or a sequence 80%> identical thereto. 27. Nucleic acid molecule comprising a nucleic acid sequence coding for a variable l ight chain region CRD of SEQ ID Nos.: 8,18, 28, 38, 48, 58, 68, 78,

88, 98, 9,19, 29, 39, 49, 59, 69, 79, 89, 99, 10, 20, 30, 40, 50, 60, 70, 80, 90 or a sequence 80% identical thereto.

28. A vector comprising a nucleic acid molecule according to any of embodiments 24 to 27.

29. A cell being transformed with a nucleic acid molecule according to any of embodiments 24 to 27 or a vector or embodiment 28.

30. Pharmaceutical composition comprising a MAGE A3 -binding antibody or binding fragment thereof of in accordance with any of embodiments 1 to 23. a nucleic acid molecule in accordance with any of embodiments 24 to 27, a vector in accordance with embodiment 28 or a cell in accordance with embodiment 29.

31. Pharmaceutical composition in accordance with embodiment 30, which does not comprise a compound capable of activating the immune system.

32. Pharmaceutical composition in accordance with embodiment 30 comprising said MAGE A3 -binding antibody or binding fragment thereof as the sole pharmaceutically active agent.

33. Pharmaceut ical composit ion in accordance with any of embodiments 30 to 32 for use in the treatment of a hyper-proliferative disease.

34. Use of a MAGEA3 -binding antibody or binding fragment thereof of in

accordance with any of embodiments 1 to 23. a nucleic acid molecule in accordance with any of embodiments 24 to 27, a vector in accordance with embodiment 28, a cell in accordance with embodiment 29 or a pharmaceutical composition in accordance with any of claims 31 to 32 in the manufacture of a medicament for treating a hyper-prol i ferati ve disease.

Method of treating a h y per-prol i ferat i ve disease by administering to a patient in need thereof a MAGEA3 -binding antibody or binding fragment thereof of in accordance with any of embodiments 1 to 23 or a pharmaceutical composition in accordance with any of embodiments 0 to 32.

Pharmaceutical composition, use or method of any of embodiments 33 to 35, wherein the hyper-prol i ferat i ve disease is characterized by expression of MAGE A3.

Pharmaceutical composition, use or method of any of embodiments 33 to 36, wherein said hyper-proliferative disease is selected from basal cell carcinoma: bladder cancer; bone cancer; central nervous system tumors; Burkitt's lymphoma; breast cancer; cervical cancer; chronic myelogenous leukemia; colon cancer; rectal cancer; colorectal cancer, esophageal cancer; Ewing family of tumors; extrahepatic bile duct cancer; gallbladder cancer; gastrointestinal stromal tumor (GIST); glioma; head and neck cancer; islet cell tumors; kaposi sarcoma; leukemia; liver cancer; lymphoma; Hodgkin's lymphoma; non- Hodgkin's lymphoma; mesothelioma; multiple myeloma plasma cell neoplasm; myeloid leukemia; nasopharyngeal cancer; neuroblastoma; small cell lung cancer; non-small cell lung cancer; oropharyngeal cancer; ovarian cancer; pancreatic cancer; parathyroid cancer; penile cancer; pharyngeal cancer;

phaeochromocytoma: pituitary tumor: prostate cancer; renal cell (kidney) cancer; respiratory tract carcinoma; retinoblastoma: skin cancer (melanoma); small intestine cancer; soft tissue sarcoma; squamous cell carcinoma;

squamous neck cancer; stomach (gastric) cancer; T-cell lymphoma: testicular cancer; throat cancer; thyroid cancer; transitional cell cancer of the renal pelvis and ureter; urethral cancer; uterine cancer; vaginal cancer; vulvar cancer and

Wilms tumor. Pharmaceutical composition, use or method of any of embodiments 33 to 36, wherein said hyper-prol ifcrat i ve disease is selected from melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and/or pancreatic cancer. Pharmaceutical composition comprising at least one tumor associated antigen (TAA ) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system. Kit of pharmaceutical compositions comprising

a) a first pharmaceutical composition comprising at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof; and b) a second pharmaceutical composition comprising at least one compound capable of activating the immune system. Pharmaceutical composition according to embodiment 39 or kit according to embodiment 40, wherein the at least one TAA binding antibody or binding fragment thereof binds to a CT antigen. Pharmaceutical composition or kit according to any of embodiments 39 to 41 , wherein the at least one TAA binding antibody or binding fragment thereof binds to a CT antigen selected from table 1. Pharmaceut ical composition or kit according to any of embodiments 39 to 42, wherein the at least one TAA binding antibody or binding fragment thereof is a monoclonal chimeric, humanized or human antibody or binding fragment thereof Pharmaceutical composition or kit according to any of embodiments 39 to 43, wherein the at least one TAA binding antibody or binding fragment thereof is a monoclonal human patient-derived antibody or binding fragment thereof. Pharmaceutical composition or kit according to any of embodiments 39 to 44, wherein the at least one TAA binding antibody or binding fragment thereof comprises a constant region selected from the IgG class.

Pharmaceutical composition or kit according to any of embodiments 39 to 45, wherein the at least one TAA binding antibody or binding fragment thereof binds to the TAA with a K_D of about 0. 1 * 10 ^L' to about 1 * 1 0 M.

Pharmaceutical composition or kit according to any of embodiments 39 to 46 wherein the TAA-antibody or binding fragment thereof and. or any other antibody or binding fragment thereof which is part of the pharmaceutical compositions or kits in accordance with any of embodiments 39 to 46 is coupled to a drug, a radioisotope, lectins, and/or a toxin.

Pharmaceutical composition or kit according to any of embodiments 39 to 47, wherein the at least one TAA binding antibody or binding fragment thereof binds to MAGEA3.

Pharmaceutical composition or kit according to any of embodiments 39 to 48, wherein the at least one TAA binding antibody or binding fragments thereof binds to MAGE A3 and is a patient-derived monoclonal human antibody or binding fragment thereof.

Pharmaceutical composition or kit according to any of embodiments 39 to 49, wherein the at least one TAA binding antibody or binding fragments thereof binds to MAGE A3 and comprises a light chain variable region and/or a heavy chain variable region, wherein

the light chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 9, 19, 29, 39, 49. 59, 69, 79, 89, 99 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ ID Nos.: 1 0, 20, 30, 40, 50, 60, 70, 80, 90, 100 or sequences at least 80% identical thereto; and/or wherein

the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 5, 1 5, 25. 35, 45, 55, 65, 75, 85, 95 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6. 16. 26. 36, 46, 56, 66, 76. 86, 96 or sequences at least 80%> identical thereto, and/or a CDR.3 selected from SEQ ID Nos.: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97 or sequences at least 80%> identical thereto.

Pharmaceutical composition or kit according to embodiment 50, wherein the at least one TAA binding antibody or binding fragments thereof binds to

MAG E A3 and comprises a light chain variable region and. or a heavy chain variable region, wherein

the light chain variable region comprises at least a CDRl selected from SEQ ID Nos.: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 9, 19, 29, 39, 49, 59, 69, 79, 89, 99 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 10, 20, 30, 40. 50. 60, 70, 80, 90, 1 00 or sequences at least 80% identical thereto; and or w herein

the heavy chain variable region comprises at least a CDRl selected from SEQ I D Nos.: 5. 15, 25, 35. 45, 55, 65, 75, 85, 95 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos. : 6, 16. 26, 36, 46, 56, 66, 76, 86, 96 or sequences at least 80%> identical thereto, and a CDR3 selected from SEQ ID Nos.: 7, 1 7, 27, 37, 47, 57, 67, 77, 87, 97 or sequences at least 80% identical thereto.

52. Pharmaceutical composition or kit according to any of embodiments 39 to 49, wherein the at least one TAA binding antibody or binding fragment thereof binds to MAGEA3 and wherein the antibody or binding fragment comprises a light chain variable region comprising SEQ ID Nos.: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and. or a heavy chain variable region comprising SEQ I D Nos.: 3, 1 , 23. 33, 43, 53, 63, 73. 83, 93 or sequences at least 80% identical thereto.

Pharmaceutical composition or kit according to embodiment 52, wherein the at least one TAA binding antibody or binding fragment thereof binds to

MAGEA3 and wherein the antibody or binding fragment comprises a light chain variable region comprising SEQ I D Nos.: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94 or sequences at least 80% identical thereto and. or a heavy chain variable region comprising SEQ ID Nos.: 3, 13. 23, 33, 43, 53, 63, 73, 83, 93 or sequences at least 80% identical thereto. 54. Pharmaceutical composition or kit according to any of embodiments 39 to 53, wherein the at least one compound capable of activating the immune system is selected from, natural stimulants or at least co-stimulants of the immune system, agonistic activators of natural stimulants or at least co-stimulants of the immune system, or antagonistic effectors of natural inhibitors or at least co- inhibitors of the immune system.

55. Pharmaceutical composition or kit according to any of embodiments 39 to 54, wherein the at least one compound capable of activating the immune system is selected from CD40L, anti-CD40 agonistic antibodies, anti-OX40 agonistic antibodies. anti-CD 137 agonistic antibodies, anti-CTLA4 antagonistic

antibodies, and anti-CD25 antagonistic antibodies.

Pharmaceutical composition or kit according to any of embodiments 39 to 55, wherein the at least one compound capable of activating the immune system is selected from CD40L, CP-870,893, SGN-40, Tremelimumab and Ipil imumab.

Pharmaceutical composition or kit according to any of embodiments 39 to 56, wherein the composition or the kit comprises at least two compounds capable of activating the immune system, of which the first compound is selected from natural stimulants or at least co-stimulants of the immune system or agonistic activators of natural stimulants or at least co-stimulants of the immune system., and of which the second compound is selected from antagonistic effectors of natural inhibitors or at least co-inhibitors of the immune system.

Pharmaceutical composition or kit according to embodiment 57, wherein the first compound capable of activating the immune system is selected from CD40L, anti-CD40 agonistic antibodies, anti-OX40 agonistic antibodies and anti-CD 137 agonistic antibodies and wherein the second compound capable of activating the immune system is selected from anti-CTLA4 antagonistic antibodies, and anti-CD25 antagonistic antibodies.

Pharmaceutical composition or kit according to embodiments 58, wherein the first compound capable of activating the immune system is selected from CD40L, CP-870,893 and SGN-40, and wherein the second compound capable of activating the immune system is selected from Tremelimumab and

Ipilimumab.

Pharmaceutical composition according embodiment 39 or any of embodiments 41 to 59, wherein the at least one TAA binding antibody or binding fragment - I l l -

thereof and the at least one compound capable of activating the immune system take the form of a bi-specific antibody or binding fragment thereof.

Pharmaceutical composition according to embodiment 60, wherein the bi- specific antibody comprises (i) a TAA binding portion and (ii) a portion acting as agonistic activator of natural stimulants or at least co-stimulants of the immune system, or antagonistic effector of natural inhibitors or at least co- inhibitors of the immune system.

Pharmaceutical composition according to embodiment 61 , wherein the bi- specific antibody comprises (i) a CT-antigen binding portion and (ii) a portion acting as anti-CD40 agonistic antibody. anti-OX40 agonistic antibody, anti- CD 1 37 agonistic antibody. anti-CTLA4 antagonistic antibody, or anti-CD25 antagonistic antibody.

Pharmaceutical composition according to embodiment 62, wherein the bi- specific antibody comprises (i) a MAGE A3 binding portion and (ii) a portion acting as anti-CD40 agonistic antibody or anti-CTLA4 antagonistic antibody.

Pharmaceutical composition according to any of embodiments 39 or 41 to 63, wherein the composition comprises additionally a cytotoxic agent. Pharmaceutical composition according to embodiment 39 or any of embodiments 41 to 64, wherein the wherein the cytoto ic agent is selected from 5-fluoro-uracil, taxanes. anthracyclines, cisplatin. carboplatin, gemcitabine, capecitabin. navelbine or zoledronate.

Kit according to any of embodiments 40 to 59, wherein the kit comprises third pharmaceutical composition comprising a cytotoxic agent. Kit according to embodiment 66, wherein the cytotoxic agent is selected from 5-fluoro-uracii, taxanes, anthracyciin.es, cispiatin, carboplatin, gemcitabine, capecitabin, navelbine or zoledronate. 68. Pharmaceutical composition or kit according to any of embodiments 39 to 67 comprising a cytotoxic agent, a CT-antigen binding antibody or binding fragment thereof and at least one compound selected from (i) natural stim.ul.ants or at least co-stimulants of the immune system, (ii) agonistic activators of natural stimulants or at least co-stimulants of the immune system and/or (iii) antagonistic effectors of natural inhibitors or at least co-inhibitors of the immune system.

Pharmaceutical composition or kit according to any of embodiments 39 to 68 comprising a cytotoxic agent, a CT-antigen binding antibody or binding fragment thereof, and at least one compound selected from agonistic activators of natural stimulants or at least co-stimulants of the immune system, or from antagonistic effectors of natural inhibitors or at least co-inhibitors of the immune system. 70. Pharmaceutical composition or kit according to any of embodiments 39 to 69 comprising a cytotoxic agent, a CT-antigen binding antibody or binding fragment thereof, at least one compound selected from agonistic activators of natural stimulants or at least co-stimulants of the immune system, and at least one compound selected from antagonistic effectors of natural inhibitors or at least co-inhibitors of the immune system.

Pharmaceutical composition or kit according to any of embodiments 68 to 70, wherein the CT-antigen binding antibody or binding fragments thereof recognizes MAGE A3, wherein the at least one compound selected from agonistic activators of natural stimulants or at least co-stimulants of the immune system is an anti-CD40 agonistic antibody and wherein the at least one compound selected from antagonistic effectors of natural inhibitors or at least co-inhibitors of the immune system is a anti-CTLA4 antagonistic antibody.

72. Combinat ion of at least one tumor associated ant igen (TAA) binding ant ibody or binding fragment thereof and at least one compound capable of activating the immune system for use in treating a patient wherein a TAA binding antibody or binding fragment thereof and at least one compound capable of activating the immune system is administered to the patient.

73. Combination for use as in embodiment 72, wherein a TAA binding antibody or binding fragment thereof and at least one compound capable of activating the immune system as mentioned in any of embodiments 41 to 63 is administered to the patient.

74. Combination for use as in embodiment 73, wherein the patient is subjected to cytoto ic treatment prior to, simultaneous ith or subsequent to administration of said combination.

Combination for use as in embodiment 74, wherein the cytotoxic treatment includes chemotherapy, radiation therapy, surgery and or hyperthermia.

Combination for use as in embodiment 75, wherein chemotherapy includes administration of agents selected from 5-fiuoro-uracil, taxanes, anthracycl in* cisplatin, carboplatin. gemcitabine, capecitabin. navelbine or zoledronate.

77. Combination for use as in embodiments 72 to 76 for treating a hyper- proliferative disease. Combination for use as in embodiment 77 for treating a hyper-pro! iferative disease, which is characterized by expression of a TAA. Combination for use as in embodiment 78, wherein said TAA is a CT antigen. Combination for use as in embodiment 79, wherein said CT antigen is

MAGE A3.

Combination for use as in any of embodiments 72 to 80, wherein said hyper- proliferative disease is selected from basal cell carcinoma; bladder cancer; bone cancer; central nervous system tumors; Burkitt's lymphoma; breast cancer; cervical cancer; chronic myelogenous leukemia; colon cancer; rectal cancer; colorectal cancer, esophageal cancer; Ewing family of tumors;

extrahepatic bile duct cancer; gallbladder cancer; gastrointestinal stromal tumor ( GIST); glioma; head and neck cancer; islet cell tumors; kaposi sarcoma;

leukemia: liver cancer; lymphoma; I lodgkin^'s lymphoma; non-Hodgkin^'s lymphoma; mesothelioma; multiple myeloma/plasma cell neoplasm; myeloid leukemia; nasopharyngeal cancer; neuroblastoma; small cell lung cancer; non- small cell lung cancer; oropharyngeal cancer;; ovarian cancer; pancreatic cancer; parathyroid cancer; penile cancer; pharyngeal cancer;

phaeochromocytoma; pituitary tumor; prostate cancer; renal cel l (kidney) cancer; respiratory tract carcinoma; retinoblastoma; skin cancer (melanoma); small intestine cancer; soft tissue sarcoma; squamous cell carcinoma;

squamous neck cancer; stomach (gastric ) cancer; T-cell lymphoma; testicular cancer; throat cancer; thyroid cancer; transit ional cell cancer of the renal pelvis and ureter; urethral cancer; uterine cancer; vaginal cancer; vulvar cancer and Wilms tumor.

Medicament for use in treating a patient wherein a pharmaceutical composition or a kit in accordance with any of embodiments 39 to 71 or a combinat ion of at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system is administered to the patient. Medicament for use as in embodiment 82, wherein the patient is subjected to cytotoxic treatment prior to, simultaneous with or subsequent to administration of a pharmaceutical composition or a kit in accordance with any of

embodiments 39 to 71 or of a combinat ion of at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system. Medicament for use as in embodiment 83, wherein the cytotoxic treatment includes chemotherapy, radiation therapy, surgery and/or hyperthermia. Medicament for use as in embodiment 84, wherein chemotherapy includes administrat ion of agents selected from 5-fluoro-uracil, taxanes, anthracyclines, cisplatin, carboplatin, gemcitabine, capecitabin, navelbine or zoledronate. Medicament for use as in embodiments 82 to 85 for treating a hyper- proliferative disease. Medicament for use as in embodiment 86 for treating a hyper-pro! i ferat i ve disease, which is characterized by expression of a TAA. Medicament for use as in embodiment 87, w herein said TAA is a CT antigen. Medicament for use as in embodiment 88, wherein said CT antigen is

MAGE A3.

Medicament for use as in any of embodiments 86 to 89, wherein said hyper- pro! iterative disease is selected from basal cell carcinoma; bladder cancer; bone cancer; central nervous system tumors; Burkitt's lymphoma; breast cancer; cervical cancer; chronic myelogenous leukemia; colon cancer; rectal cancer; colorectal cancer, esophageal cancer; Ewing family of tumors;

extrahepatic bile duct cancer; gallbladder cancer; gastrointestinal stromal tumor

(GIST); glioma; head and neck cancer; islet cell tumors; kaposi sarcoma;

leukemia; liver cancer; lymphoma; Hodgkin's lymphoma; non-Hodgkin's lymphoma: mesothelioma; multiple myeloma plasma cell neoplasm; myeloid leukemia; nasopharyngeal cancer; neuroblastoma; small cell lung cancer; non- small cell lung cancer; oropharyngeal cancer;; ovarian cancer; pancreatic cancer; parathyroid cancer; penile cancer; pharyngeal cancer;

phaeochromocytoma; pituitary tumor; prostate cancer; renal cell (kidney) cancer; respiratory tract carcinoma; retinoblastoma; skin cancer (melanoma); small intestine cancer; soft tissue sarcoma; squamous cell carcinoma;

squamous neck cancer; stomach (gastric) cancer; T-cell lymphoma; testicular cancer; throat cancer; thyroid cancer; transitional cell cancer of the renal pelvis and ureter; urethral cancer; uterine cancer; vaginal cancer; vulvar cancer and Wilms tumor.

Medicament for use as in any of embodiments 82 to 90, wherein the at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system are as mentioned in any of embodiments 39 to 71.

Use of a pharmaceutical composition or a kit in accordance with any of embodiments 39 to 71 or a combination of at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system in the manufacture of a medicament for treating a patient. Use as in embodiment 92, wherein the patient is subjected to cytotoxic treatment prior to, simultaneous with or subsequent to the administration of a pharmaceutical composition or a kit in accordance with any of embodiments 39 to 71 or of a combination of at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system.

94. Use as in embodiment 93. wherein the cytotoxic treatment includes

chemotherapy, radiation therapy, surgery and/or hyperthermia.

95. Use as in embodiment 94, wherein chemotherapy includes administration of agents selected from 5-fluoro-uracil, taxanes, anthracyclines, cisplatin, carboplatin, gemcitabine, capecitabin, navelbine or zoledronate. 96. Use as in embodiments 92 to 95 for treating a hyper-pro! iferative disease.

97. Use as in embodiment 96 for treating a hyper-proliferative disease, which is characterized by expression of a TAA. 98. Use as in embodiment 97, wherein said TAA is a CT antigen.

99. Use as in embodiment 98, wherein said CT antigen is MAGEA3.

100. Use as in any of embodiments 92 to 99, wherein said hyper-proliferative

disease is selected from basal cell carcinoma; bladder cancer; bone cancer; central nervous system tumors; Burkitt^'s lymphoma; breast cancer; cervical cancer; chronic myelogenous leukemia: colon cancer; rectal cancer; colorectal cancer, esophageal cancer; Ewing family of tumors; extrahepatic bile duct cancer; gallbladder cancer; gastrointestinal stromal tumor (GIST); glioma; head and neck cancer; islet cell tumors; kaposi sarcoma; leukemia; liver cancer; lyniphoma; Hodgkin's lymphoma; non-Hodgkin's lymphoma; mesothel ioma; multiple myeloma plasma cell neoplasm; myeloid leukemia; nasopharyngeal cancer; neuroblastoma; small cell lung cancer; non-small cell lung cancer; oropharyngeal cancer;; ovarian cancer; pancreatic cancer; parathyroid cancer; penile cancer; pharyngeal cancer; phaeochromocytoma; pituitary tumor;

prostate cancer; renal cell (kidney) cancer; respiratory tract carcinoma;

retinoblastoma; skin cancer (melanoma); small intestine cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; T-cell lymphoma; testicular cancer; throat cancer; thyroid cancer; transitional ceil cancer of the renal pelvis and ureter; urethral cancer; uterine cancer; vaginal cancer; vulvar cancer and Wilms tumor.

Use as in any of embodiments 92 to 1 00, wherein the at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system are as mentioned in any of embodiments 41 to 63. Method of treating a patient by administering a pharmaceutical composition or a kit in accordance with any of embodiments 39 to 71 or a combination of at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system is administered to the patient.

Method as in embodiment 102, wherein the patient is subjected to cytotoxic treatment prior to, simultaneous with or subsequent to the administration of a pharmaceutical composition or a kit in accordance with any of embodiments 39 to 7 1 or of a combination of at least one tumor associated antigen (TAA ) binding ant ibody or binding fragment thereof and at least one compound capable of activating the immune system. 104. Method as in embodiment 103, wherein the cytotoxic treatment includes chemotherapy, radiation therapy, surgery and/or hyperthermia.

105. Method as in embodiment 104, wherein chemotherapy includes administration of agents selected from 5-fluoro-uracil, taxanes, anthracyclines, cisplatin, carbop!atin, gemcitabine, capecitabin. navelbine or zoledronate.

106. Method as in embodiments 102 to 105 for treating a hyper-prol i erative

disease.

107. Method as in embodiment 106 for treating a hyper-prol iferative disease, which is characterized by expression of a TAA.

108. Method as in embodiment 1 07, w herein s id TAA is a CT antigen.

109. Method as in embodiment 108, w herein said CT antigen is MAGE A3.

1 10. Method as in any of embodiments 102 to 109, wherein said hyper-proliferative disease is selected from basal cell carcinoma; bladder cancer; bone cancer; central nervous system tumors; Burkitt^'s lymphoma; breast cancer; cervical cancer; chronic myelogenous leukemia; colon cancer; rectal cancer; colorectal cancer, esophageal cancer; Ewing family of tumors; extrahepatic bile duct cancer; gallbladder cancer; gastrointestinal stromal tumor (GIST); gl ioma; head and neck cancer; islet cell tumors; kaposi sarcoma; leukemia: liver cancer; lymphoma; Hodgkin^'s lymphoma: non-Hodgkin's lymphoma: mesothelioma; multiple myeloma plasma cell neoplasm; myeloid leukemia; nasopharyngeal cancer; neuroblastoma: small cell lung cancer; non-small cell lung cancer; oropharyngeal cancer;; ovarian cancer; pancreatic cancer: parathyroid cancer; penile cancer; pharyngeal cancer; phaeochromoc y t o m a : pituitary tumor;

prostate cancer; renal eel 1 (kidney) cancer; respiratory tract carcinoma; retinoblastoma; skin cancer (melanoma ); small intestine cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; T-ccll lymphoma: testicular cancer; throat cancer; thyroid cancer; transitional cell cancer of the renal pelvis and ureter; urethral cancer; uterine cancer; vaginal cancer; vulvar cancer and Wilms tumor.

Method as in any of embodiments 102 to 1 10, wherein the at least one tumor associated antigen (TAA) binding antibody or binding fragment thereof and at least one compound capable of activating the immune system are as mentioned in any of embodiments 39 to 71.

MAGEA3 binding antibody or binding fragment thereof according to any of embodiments 1 to 23 for use in diagnosis. Diagnostic composition comprising a MAGE A3 binding antibody or binding fragment thereof according to any of embodiments 1 to 23.

MAG E A3 binding antibody or binding fragment thereof for use as in embodiment 1 12 or diagnostic composition as in embodiment 1 13, wherein hyperproiiferative disease is diagnosed. MAGE A3 binding antibody or binding fragment thereof for use or diagnostic composition as in embodiment 1 14, wherein the hyperproiiferative disease is selected from basal cell carcinoma; bladder cancer; bone cancer; central nervous system tumors; Burkitt's lymphoma: breast cancer; cervical cancer; chronic myelogenous leukemia; colon cancer; rectal cancer; colorectal cancer, esophageal cancer; Ewing family of tumors; extrahepatic bile duct cancer; gallbladder cancer; gastrointestinal stromal tumor (GIST); glioma; head and neck cancer; islet cell tumors; kaposi sarcoma; leukemia; liver cancer;

lymphoma; Hodgkin's lymphoma; non-Hodgkin's lymphoma; mesothelioma; multiple myeloma plasma cell neoplasm; myeloid leukemia; nasopharyngeal cancer; neuroblastoma; small cell lung cancer; non-small cell lung cancer; oropharyngeal cancer:; ovarian cancer; pancreatic cancer; parathyroid cancer; penile cancer; pharyngeal cancer; phaeochromocytoma; pituitary tumor;

prostate cancer; renal cell (kidney) cancer; respiratory tract carcinoma;

retinoblastoma; skin cancer (melanoma); small intestine cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; T-cel! lymphoma; testicular cancer; throat cancer; thyroid cancer; transitional cell cancer of the renal pelvis and ureter; urethral cancer; uterine cancer; vaginal cancer; vulvar cancer and Wilms tumor. . MAGEA3 binding antibody or binding fragment thereof for use or diagnostic composition as in embodiment 1 14 or 1 15, wherein the hyperproliferative disease is characterized by an overexpression of MAGEA3 and/or MAGEA6. . MAGEA3 binding antibody or binding fragment thereof for use or diagnostic composition as in embodiments 1 14 to 1 16, wherein said hyperproliferative disease is selected from melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and. or pancreatic cancer. . A method of diagnosing a hyperproliferative disease in a human or animal individual comprising at least the steps of:

a. Testing a sample of said huma or animal individual for expression of at least

MAGEA3 by using an MAGEA3 binding antibody or binding fragment thereof according to any of embodiments 1 to 23;

b. Comparing with expression of at least MAGEA3 in a control sample;

c. Determining the occurrence and/or likely development of a hyperproliferative disease by comparing the data obtained in steps a) and b).

A method of data acquisition comprising at least the steps of: a. Administering a MAGE A3 binding antibody or binding fragment thereof according to any of embodiments 1 to 23 to human or animal individual; b. Determining the distribution of said MAGE A3 binding antibody or binding fragment thereof in said human or animal indiv idual: and

c. Determining expression of at least MAGEA3 in said human or animal

individual by using a MAGE A3 binding antibody or binding fragment thereof according to any of embodiments 1 to 23. . Method according to embodiment 1 18 or 1 19, wherein said wherein the hyperproliferative disease is selected from basal ceil carcinoma; bladder cancer; bone cancer; central nervous system tumors; Burkitt's lymphoma; breast cancer; cervical cancer; chronic myelogenous leukemia; colon cancer; rectal cancer; colorectal cancer, esophageal cancer; Ewing family of tumors; extrahepatic bile duct cancer; gallbladder cancer; gastrointestinal stromal tumor (GIST); glioma: head and neck cancer; islet cell tumors; kaposi sarcoma;

leukemia: liver cancer; lymphoma: Hodgkin^'s lymphoma: non-Hodgkin^'s lymphoma; mesothelioma; multiple myeloma plasma cell neoplasm; myeloid leukemia; nasopharyngeal cancer; neuroblastoma; small cell lung cancer; non- small ceil lung cancer; oropharyngeal cancer;; ovarian cancer; pancreatic cancer; parathyroid cancer; penile cancer; pharyngeal cancer;

phaeochromocytoma; pituitary tumor; prostate cancer; renal cell (kidney) cancer; respiratory tract carcinoma; retinoblastoma; skin cancer (melanoma); small intestine cancer; soft tissue sarcoma; squamous ceil carcinoma;

squamous neck cancer; stomach (gastric) cancer; T-cell lymphoma; testicular cancer; throat cancer; thyroid cancer; transitional cell cancer of the renal pelvis and ureter; urethral cancer; uterine cancer; vaginal cancer; vulvar cancer and Wilms tumor. Method according to any of embodiments 1 18 to 120, wherein the

hyperprol i ferati ve disease is characterized by an overexpression of MAGE A3 and/or MAGEA6.

Method according to any of embodiments 1 18 to 121 , wherein said

hyperproliferative disease is selected from melanoma, breast cancer, ovarian cancer, non-small cell lung cancer, multiple myeloma and. or pancreatic cancer.

123. Isolated monoclonal MAG E A3-bindi ng antibody or binding fragment thereof according to any of embodiments 1., 2., 3., 4., 5., 6., 7., 8., 9., 10., 1 1., 12., 13. 14., 15., 16., 17., 18., 19., 20., 21., 22., or 23., wherein said antibody is a human monoclonal patient-derived MAGEA3 binding antibody or binding fragment thereof. 124. Pharmaceutical composition according to any of embodiments 30., 31., 32., 33., 36., 37., or 38., use according to any of embodiments 34., 36., 37., or 38., or method according to any of embodiments 35.. 36., 37.. or 38., wherein said antibody is a human monoclonal patient-derived MAGE A3 binding antibody or binding fragment thereof.

125. Pharmaceutical, composition according to any of embodiments 39., 41., 42., 43., 44., 45., 46.. 47., 48., 49.. 50., 5 1 ., 52., 53., 54., 55., 56., 57., 58., 59., 60.. 61., 62., 63.. 64., 65.. 68., 69., 70., or 71 ., or kit according to any of

embodiments 40., 4 1 .. 42., 43., 44., 45., 46.. 47.. 48., 49., 50.. 5 1 ., 52., 53., 54., 55., 56.. 57., 58.. 59., 66., 67., 68., 69., 70., or 71., wherein said antibody is a human monoclonal patient-derived MAGE A3 binding antibody or binding fragment thereof. Combination according to any of embodiments 72., 73., 74., 75., 76., 77., 78., 79., 80., or 81., wherein said antibody is a human monoclonal patient-derived MAGE A3 binding antibody or binding fragment thereof.

Medicament according to any of embodiments 82., 83., 84., 85., 86., 87., 88., 89., 90., or 91., wherein said antibody is a human monoclonal patient-derived MAGEA3 binding antibody or binding fragment thereof.

Use according to any of embodiments 92., 93., 94., 95., 96., 97., 98., 99., 100., 101., , wherein said antibody is a human monoclonal patient-derived MAGE A3 binding antibody or binding fragment thereof.

Method according to any of embodiments 102., 1 03., 104., 105., 106., 107., 108., 1 09., 1 10., or 1 1 1., wherein said antibody is a human monoclonal patient-derived MAGEA3 binding antibody or binding fragment thereof. MAG EA3 binding antibody or binding fragment thereof for use in accordance with any of embodiments 1 12., 1 14., 1 15., 1 16., or 1 17., or diagnostic composition according to any of embodiments 1 13., 1 14., 1 15., 1 16., or 1 17., wherein said antibody is a human monoclonal patient-derived MAGEA3 binding antibody or binding fragment thereof.

Method according to any of embodiments 1 18., 1 19., 120., 121., or 122., wherein said antibody is a human monoclonal patient-derived MAGEA3 binding antibody or binding fragment thereof.

Claims

Isolated monoclonal MAGEA3 binding antibody or binding fragment thereof, which comprises a light chain variable region and or a heavy chain variable region, wherein

the light chain variable region comprises at least a C^'DR l selected from SEQ ID Nos.: 8 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 9 or sequences at least 80% identical thereto, and a CDR3 selected from SEQ ID Nos.: 10 or sequences at least 80% identical thereto; and or wherein

the heavy chain variable region comprises at least a CDR.1 selected from SEQ ID Nos.: 5 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID Nos.: 6 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ ID Nos.: 7 or sequences at least 80%> identical thereto.

Isolated monoclonal MAGE A3 binding antibody or binding fragment thereof according to claim 1 , which comprises a light chain variable region comprising SEQ ID Nos.: 4 or sequences at least 80% identical thereto and a heavy chain variable region comprising SEQ I D Nos.: 3 or sequences at least 80% identical thereto.

Isolated monoclonal MA G E A3 -b ind i ng antibody or binding fragment thereof according to claims 1 or 2, which binds to an epitope comprising SEQ ID No. 106.

Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to any of claims 1 to 3, which binds to an epitope comprising SEQ ID No. 107.

Isolated monoclonal MAGE A3 -binding antibody or binding fragment thereof according to any of claims 1 to 4, which binds to an epitope comprising SEQ ID No. 108.

Isolated monoclonal MAGEA3 -binding antibody or binding fragment thereof according to any of claims 1 to 5, which docs not bind to MAGEA4, MAGEA l and MAGE A 10.

Isolated monoclonal M AG EA3 -binding antibody or binding fragment thereof according to claim 6, which does not bind MAGEA2.

Pharmaceutical composition comprising a MAGE A3 -binding antibody or binding fragment thereof of in accordance with any of claims 1 to 7.

MAGEA3 -binding antibody or binding fragment thereof in accordance w ith any of claims 1 to 7 or pharmaceutical composition in accordance with claim 8 for use in the treatment of a hyper-proliferative disease.

MAGEA3 -binding antibody or binding fragment thereof in accordance with any of claims 1 to 7 or pharmaceutical composition in accordance with claim 8 for use as in claim 9 wherein said hyper-prol i ferat i ve disease is selected from basal cell carcinoma; bladder cancer; bone cancer; central nervous system tumors; Burkitt's lymphoma; breast cancer; cervical cancer; chronic myelogenous leukemia; colon cancer; rectal cancer; colorectal cancer, esophageal cancer; Ewing family of tumors; extrahepatic bile duct cancer; gallbladder cancer; gastrointestinal stromal tumor (G IST); glioma; head and neck cancer; islet cell tumors; kaposi sarcoma; leukemia; liver cancer;

lymphoma; Hodgkin's lymphoma; non-Hodgkin's lymphoma; mesothelioma; multiple myeloma plasma cell neoplasm; myeloid leukemia; nasopharyngeal cancer; neuroblastoma; small cell lung cancer; non-smal l cell lung cancer; oropharyngeai cancer; ovarian cancer; pancreatic cancer; parathyroid cancer; penile cancer; pharyngeal cancer; phaeochromocytoma; pituitary tumor;

prostate cancer; renal ceil (kidney) cancer; respiratory tract carcinoma;

retinoblastoma; skin cancer (melanoma); small intestine cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; T-ceil lymphoma; testicular cancer; throat cancer; thyroid cancer; transitional ceil cancer of the renal pelvis and ureter; urethral cancer; uterine cancer; vaginal cancer; vulvar cancer and Wilms tumor.

MAGE A3 -binding antibody or binding fragment thereof in accordance with any of claims 1 to 7 or pharmaceutical composition in accordance with claim 8 for use as in claims 9 or 10, wherein the hyper-proliferative disease is characterized by expression of MAGEA3.

12. MAGE A3 -binding antibody or binding fragment thereof in accordance with any of claims 1 to 7 or pharmaceutical composition in accordance with claim 8 for use as in any of claims 9 to 1 1 , wherein the hyper-proliferative disease is characterized by expression of MAGEA3 and wherein said hyper-proliferative disease is selected from, melanoma, breast cancer, ovarian cancer, non-small ceil lung cancer, multiple myeloma and/or pancreatic cancer.

13. Diagnostic composition comprising a MAGE A3 -binding antibody or binding fragment thereof in accordance with any of claims 1 to 7.

MAGE A3 -binding antibody or binding fragment thereof according to any of claims 1 to 7 for use in diagnosing a hyperproiiferative disease.